Next Article in Journal
Changes in Sleep Patterns during Pregnancy and Predictive Factors: A Longitudinal Study in Saudi Women
Next Article in Special Issue
Dietary Therapy in Prevention of Cardiovascular Disease (CVD)—Tradition or Modernity? A Review of the Latest Approaches to Nutrition in CVD
Previous Article in Journal
Effects of Fermented Milk Containing Bifidobacterium animalis Subsp. lactis MN-Gup (MN-Gup) and MN-Gup-Based Synbiotics on Obesity Induced by High Fat Diet in Rats
Previous Article in Special Issue
The Impact of Chronic Kidney Disease on Nutritional Status and Its Possible Relation with Oral Diseases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 14
Issue 13
10.3390/nu14132632
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Roles and Pathogenesis Mechanisms of a Number of Micronutrients in the Prevention and/or Treatment of Chronic Hepatitis, COVID-19 and Type-2 Diabetes Mellitus

by
Khalid M. Sumaily
Clinical Biochemistry Unit, Department of Pathology, College of Medicine, King Saud University, Riyadh P.O. Box 145111, Saudi Arabia
Nutrients 2022, 14(13), 2632; https://doi.org/10.3390/nu14132632
Submission received: 14 May 2022 / Revised: 18 June 2022 / Accepted: 21 June 2022 / Published: 24 June 2022
(This article belongs to the Special Issue Nutrition for Prevention and Control of Chronic Degenerative Diseases and COVID-19)
Browse Figures
Versions Notes

Abstract

:
A trace element is a chemical element with a concentration (or other measures of an amount) that is very low. The essential TEs, such as copper (Cu), selenium (Se), zinc (Zn), iron (Fe) and the electrolyte magnesium (Mg) are among the most commonly studied micronutrients. Each element has been shown to play a distinctive role in human health, and TEs, such as iron (Fe), zinc (Zn) and copper (Cu), are among the essential elements required for the organisms’ well-being as they play crucial roles in several metabolic pathways where they act as enzyme co-factors, anti-inflammatory and antioxidant agents. Epidemics of infectious diseases are becoming more frequent and spread at a faster pace around the world, which has resulted in major impacts on the economy and health systems. Different trace elements have been reported to have substantial roles in the pathogenesis of viral infections. Micronutrients have been proposed in various studies as determinants of liver disorders, COVID-19 and T2DM risks. This review article sheds light on the roles and mechanisms of micronutrients in the pathogenesis and prevention of chronic hepatitis B, C and E, as well as Coronavirus-19 infection and type-2 diabetes mellitus. An update on the status of the aforementioned micronutrients in pre-clinical and clinical settings is also briefly summarized.

1. Introduction

Trace elements (TEs), also known as trace metals, are chemical elements with a concentration (or other measures of an amount) that is very low [1]. TEs are constituents of every living organism and despite being present in relatively small amounts, they play vital roles in the growth, development as well as the general well-being of the body’s organisms [2]. The immune system requires a high supply of certain TEs to accomplish the essential functions needed in defence and surveillance [2,3,4,5,6,7]. Some vitamins and trace elements (TEs) are reported to have key roles to cope with viral infections, such as chronic hepatitis [2,3,4,5,6,7], and COVID-19 [8,9,10], in addition to metabolic disorders, such as type-2 diabetes mellitus (T2DM) [9,11,12].
The essential TEs, such as copper (Cu), selenium (Se), zinc (Zn) and iron (Fe), are among the most commonly studied micronutrients [13]. While every element has its own distinctive role in human health, TEs, such as iron (Fe), zinc (Zn) and copper (Cu), are considered essential for the organisms’ well-being due to their involvement in several metabolic pathways where they play roles as enzyme co-factors, anti-inflammatory and antioxidant agents [14]. The homeostasis of essential trace elements is maintained by the liver [15]. Therefore, an impaired liver function usually results in certain disturbances in the TEs metabolism, which leads to initiating oxidative stress and consequently results in inflammatory and/or fibrotic alterations in the liver [4].
Hepatitis is a viral infection that is characterized by an inflammation in the liver. Although this inflammation could develop concurrently or result from alcoholic and non-alcoholic steatosis, it can also be caused solely by a viral infection [16]. Recently, the impaired metabolism of a number of trace elements has been shown to have a role in the hepatitis virus infection process. Some trace elements, such as copper (Cu), zinc (Zn), selenium (Se) and iron (Fe), were shown to play a direct role in the infection and the immune rejection against hepatitis C virus (HCV) [17].
Studies have been recently conducted and indicated the benefits of using micronutrients as a natural approach to manage the infectious diseases that affect the respiratory system [18,19,20,21]. Given the current COVID-19 pandemic, which has a high mortality rate, particularly in critically ill patients [12], many studies have been conducted to distinguish the different clinical symptoms; however, the data concerning its pathology as well as the cellular responses to this virus are still limited [22].
Therefore, studies with different interventions have been recently conducted to manage COVID-19, which includes the studying and assessment of micronutrients and their roles in this viral infection [23]. Dietary management was recently proposed as a strategy that minimizes the potential risks of COVID-19 infection [24]. The adjuvant supply of certain important micronutrients that function as positive modulators in the immune system was shown to provide a further support to this strategy, in which some vitamins, such as vitamin A, B6, B12, C, D and E, as well as some essential trace elements, including zinc (Zn), iron (Fe), selenium (Se) and copper (Cu), as well as electrolytes, such as magnesium (Mg), are considered promising [25].
On the other hand, trace element imbalances may have a negative impact on biological processes that are related to fatal diseases, such as type-2 diabetes mellitus (T2DM) [26]. Studies have been performed to evaluate the relationship between the serum levels of various trace elements and metabolic disorders, such as T2DM [2,23]. Many studies have observed a direct association between a number of micronutrients and type-2 diabetes mellitus.
Some micronutrients, such as chromium (Cr), magnesium (Mg), vanadium (V), zinc (Zn), manganese (Mn), molybdenum (Mo) and selenium (Se), were shown to potentiate the insulin action by reducing the levels of blood glucose [26,27]. A number of mechanisms were proposed in regard of the potentiation of insulin by trace elements, and these include activating insulin receptor sites, acting as cofactors for some enzyme involved in the metabolism of glucose, increasing the sensitivity of insulin and exerting their antioxidant effects to prevent tissue peroxidation [28].
The Diabetes Prevention Program (DPP) has shown that a change in lifestyle, (i.e., weight loss, weight maintenance and physical activity) can decrease the incidence of T2DM by 58% [29]. However, implementing these interventions in the real life has been shown to be problematic. Thus, it is urgently needed to discover other preventive interventions that can be provided as real-world solutions [30]. Advances in the techniques used in molecular biology have opened the doors for researchers to provide further clarification to the novel mechanisms of TEs that cause these metabolic abnormalities [27].
Despite the recent reviews that have assessed the underlying mechanisms of TEs in the prevention and/or development of metabolic abnormalities, clinical studies and laboratory analyses are still few, and the database available is limited [13]. Table 1 provides a summary of the pathogenic pathways and roles of a number of micronutrients in the prevention and/or treatment of chronic hepatitis, COVID-19 and T2DM [28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59]. This review article assesses the roles and the importance of a number of micronutrients in chronic hepatitis, COVID-19 and T2DM, while giving a brief summary on the therapeutic and preventive mechanisms as well as the current status of zinc (Zn), selenium (Se), copper (Cu), iron (Fe) and magnesium (Mg) in preclinical and clinical settings.

2. Roles and Mechanisms of Trace Elements in Viral Infections

The epidemics of infectious diseases are becoming more frequent and spreading at a faster pace around the world, which results in major impacts on the economy and health systems [62]. Different trace elements were reported to have different roles in the pathogenesis of viral infections, including the viruses’ survival, the attachment to their host as well as the characterization of the viral infections that occur as a result of deregulating metal homeostasis in the course of infection [9]. For instance, many studies have revealed that zinc (Zn) [8], copper (Cu) [10], and iron (Fe) [63], are some of the metals that commonly bind to the proteins that were shown to have an association in the occurrence of viral infections [21]. Therefore, this section highlights the biochemical mechanisms and roles by which these trace elements act in the immune system against chronic hepatitis and COVID-19 viral infections in particular.

2.1. Roles and Mechanism of Trace Elements in Chronic Hepatitis

It is believed that the replication of the virus is considered as the driving force in viral infections that cause liver damage [64]. International guidelines have shown that the primary therapeutic goal in the treatment of chronic Hepatitis B virus (HBV) is to permanently suppress the replication of the virus [65]. Some publications have reported that serum concentration of trace elements, such as zinc (Zn), selenium (Se), copper (Cu) and iron (Fe), showed a high sensitivity for assessing hepatic disorders [66]. In addition, studies have shown that these aforementioned trace elements play key roles in liver diseases and more specifically degenerative liver disorders [67].
Although the plasma concentrations of these trace elements were shown to change during the majority of infections, it is still unclear whether the infected tissues (i.e., the liver) experience the same alteration [65]. It is believed that the activity of HBV is altered by the change of the serum levels of these major trace elements [19]. However, the variation of plasma levels of trace elements in viral infections and their effect on creating a tissue injury is still unknown [3].
The mechanisms by which viral infections cause liver damage are presented through extensive inflammation and oxidative stress, which result from producing excessive reactive oxygen species (ROS) [68]. This section highlights a number of studies that addressed the relationship between the development of chronic hepatitis and the effects that some trace elements, such as zinc (Zn), selenium (Se), iron (Fe) and copper (Cu), may have in the different types of hepatitis viral infection.

2.1.1. Zinc (Zn)

Zinc (Zn) is an essential trace element that was reported to increase the susceptibility of developing many diseases due to its involvement in various metabolic processes that have a vital role in the immune system [69]. Liver is the organ that has the main responsibility of metabolizing zinc (Zn) [7]. Studies have shown that the levels of serum zinc (Zn) are often lowered in patients who have chronic liver diseases [70]. Other studies have shown that zinc (Zn) deficiency altered the functions of hepatocytes as well as the immune responses in some inflammatory liver diseases [71], which as a consequence, initiated some metabolic abnormalities that include insulin resistance [72], iron (Fe) overload [11], hepatic steatosis [73], and hepatic encephalopathy in patients suffering from a chronic liver disease [74].
On the other hand, data collected on the zinc (Zn) supplementation effect were conflicting [69], and even though the use of zinc (Zn) supplementation has been shown to help in alleviating some of the symptoms detected in chronic liver diseases, in addition to the positive effects it had on metabolic abnormalities as reported in some experimental models, there is still no strong evidence confirming the beneficial effects of using zinc (Zn) supplementation for patients with liver cirrhosis [75].
Previous studies have suggested that the antiviral state that activates the innate immune response involved the down-regulation of HBV mRNA [43,44,76]. In a study, it was demonstrated that the two human zinc finger antiviral protein (hZAP) isoforms (i.e., h-ZAP S and h-ZAP L) inhibited the replication of HBV in human hepatocyte-derived cells via the viral pgRNA posttranscriptional down-regulation [77]. In a mechanistic manner, the zinc finger motif-containing N-terminus of hZAP has the responsibility of reducing HBV RNA, as well as altering the four zinc finger motifs’ integrity in order to facilitate the binding of ZAP to HBV RNA and therefore fulfil the expected antiviral function [78].
The results of a similar study demonstrated that an upregulation of ZAP in cultured primary human hepatocytes as well as hepatocyte-derived cells was detected as a result of either IFN-α treatment or the activation of IPS-1. Knock-down of the expression of ZAP was shown to increase the HBV RNA levels and cause a partial attenuation of the antiviral effect stimulated by IPS-1 in the cell cultures used [31]. Consequently, ZAP was demonstrated as an intrinsic host antiviral factor that is active against HBV and plays a major role in the HBV replication innate control [79].
Another study has focused on analysing the roles and mechanisms of zinc (Zn) in the pathogenesis of hepatitis C virus (HCV) and have reported that the oxidative stress causes a disruption in zinc (Zn) homeostasis, in particular, in the signalling molecule and secondary messenger through the redox process, resulting in HCV-mediated mitochondrial dysfunction [80]. It is worth mentioning that, upon viral eradication using interferon (IFN)-based regimens or direct-acting anti-viral (DAA) therapy, zinc (Zn) serum levels were shown to rise significantly, which reflects the hepatic inflammation’s resolution as well as an improvement in the gut absorption [33].
Similarly, it was demonstrated in another study that a larger decline in the serum levels of zinc (Zn) following an IFN-α treatment resulted in an increase in the baseline zinc (Zn) levels, which in such conditions, zinc (Zn) was shown to mainly localize in the liver, causing a stimulation of the metallothionein (MT) expression and the anti-viral activity. The roles of serum zinc (Zn) and methallothionein in acute versus chronic hepatitis C virus (HCV) [4], are shown in Figure 1.
IFN-L3 is a proinflammatory cytokine, which has shown a potent antiviral activity against both acute and chronic infections [81]. In a recent study, zinc (Zn) was found to cause an inhibition of the IFN-L3 binding to its receptor (IFNLR1). The results demonstrated that zinc (Zn) enhanced the replication of both HCV as well as H1N1 (human influenza) in mammalian cells by causing an inhibition of the IFN-L3 function [82]. Reduced plasma zinc (Zn) levels and a reduction in the hepatic metallothionein (MT) expression were both detected in chronic HCV infection [34].
Therefore, studies have suggested that the mediated modulation of zinc (Zn) in the IFN-l signalling pathway, has been shown to play a significant role in the determination of disease outcome in patients with HCV [82,83]. A study that was conducted recently has analysed the antiviral action of zinc (Zn) in patients with hepatitis E virus (HEV) infection. In this study, zinc (Zn) treatment was shown to significantly inhibit the replication of the virus in the human hepatoma cell culture of genotype-1 and genotype-3 HEV. The results demonstrated that adding zinc (Zn) has inhibited the RNA-dependent RNA polymerase (RdRp) viral activity in vitro [7]. However, these observed data of the antiviral effect of zinc (Zn) could be related to direct and indirect actions of this trace element on multiple virus or host targets or processes [83].

2.1.2. Selenium (Se)

Selenium (Se) has been studied for its involvement in the liver pathology and studies have reported that a deficiency in the serum levels of selenium (Se) was shown to induce a systematic redox imbalance as well as an inflammation in the blood [84]. Several selenoproteins including thioredoxin reductases (TXNRD), selenoproteins P (SELENOP), SELENOS and SELENOK and glutathione peroxidases 1 (GPX1) were studied and the results demonstrated that selenocysteines have a unique chemical reactivity and the ability to repair and mitigate liver damage caused by reactive oxygen species (ROS) [85].
Recently, an epidemiological study was conducted to assess the relationship between the serum levels of selenium (Se) and the risk of developing chronic liver diseases. This study reported that selenium (Se) serum levels are decreased when Se is at the optimal level in patients with hepatitis, cirrhosis and liver cancer as compared to healthy individuals [86]. However, these results were not shown to be consistent and the relationship in chronic liver diseases with different severities was controversial [87].
Furthermore, studies reported that a maintenance of an adequate amount of selenium (Se) in the body or the use of selenium (Se) supplementation in the case of selenium (Se) deficiency could have beneficial effects on patients who have chronic liver diseases, when compared with the controls in the same region [68,88]. In the case of CHC, the effect of selenium (Se) deficiency remains unclear. CHC infection has been reported in some studies to cause a reduction in the serum levels of selenium (Se), which have also been shown to decrease even more after the development of HCV-related cirrhosis [35]. These data were further supported by other studies, which have reported a decline in serum levels of selenium (Se) in proportion to the hepatic fibrosis degree [89].
In addition, the activity of glutathion peroxidase (GPx) was shown to reduce along with the serum levels of selenium (Se) in patients with CHC, which uncovered a possible mechanism for stimulating oxidative stress by CHC due to the deficient selenium (Se) levels [36]. However, the reduction of serum selenium levels in CHC patients was shown to be insignificant, which suggested that the alcohol consumption is the major variable affecting selenium (Se) levels [4]. HCV was reported in an in vitro study to inhibit gastrointestinal-GPx expression, which resulted in an increase in the replication of the virus [90].
In addition, low serum selenium (Se) levels that were reported in CHC patients were shown to have a positive association with the lowered GPx activity; however, this observation has not been detected in HCV genotype or HCV-RNA load [91]. While these data do not give a direct indication that HCV results in a decreased selenium (Se) level, they still are raising the possibility to replace selenium (Se) as a therapeutic supplement in order to boost anti-oxidant as well as antiviral activities [4]. The role of dietary selenium (Se) in viral infections [92], is represented in Figure 2.

2.1.3. Iron (Fe)

An enhancement in the progression of chronic HBV infection along with the patient’s poor prognosis were related to the high iron (Fe) serum levels [37]. In a study that was conducted in 2018, Gao et al. found that the levels of serum iron (Fe) and serum ferritin were increased in patients with chronic hepatitis B (CHB). It was observed in the same study that the levels of serum transferrin and the total binding capacity decreased while the transferrin saturation increased [38]. Other studies suggested that some inflammatory factors, such as liver injury, micro ribonucleic acid −122, viral activity, ROS, IL-6 as well as other factors could result in an iron (Fe) overload in patients with CHB [39].
In the case of chronic hepatitis C (CHC), iron (Fe) liver deposits were detected in 7–61% of patients depending on the severity of the disease [93]. Recent studies have suggested that elevated levels of iron (Fe) in the liver play a critical role in the liver disease progression as well as increasing the risk for developing liver cancer [94]. Moreover, other studies have concluded that giving iron (Fe) supplementation in the case of haemodialysis for patients who have hepatitis C virus (HCV) infection resulted in a significant increase in the levels of transaminase after only three months of therapy [4].
Mesenchymal hepatic iron (Fe) overload in patients with HCV infection was reported to result from the hepatocyte necrosis, which leads to releasing the ferritin and iron (Fe) uptake of both macrophages and Kupffer cells [95]. This was suggested to have a contribution to the release of the cytokine, which triggers liver inflammation and fibrosis [94]. Other studies have focused on the role of the hemochromatosis gene (HFE) on the cellular level and have concluded that it promotes iron (Fe) overload in patients with HCV infection [96].
Further studies have concluded that homozygous and heterozygous mutations in HFE C282Y have led to hepatic iron (Fe) overload, which promoted steatosis and fibrosis in the liver of patients with HCV infection [97]. Nonetheless, the beneficial roles of iron (Fe) on the translation of HCV in diverse HCV genotypes have been reported in recent studies; however, it is still unclear whether iron (Fe) suppresses or promotes the replication of HCV [39]. It has been clarified in other recent discussions whether iron (Fe) promotes the replication of HCV in liver cells [98], and recent studies have reported that the replication of HCV has been shown to enhance in iron (Fe) overloaded macrophages as compared to the iron (Fe) physiological level.
The results suggested that the reasons behind this might be due to the high oxidative stress in the macrophages as well as the impairment in the immune function [40]. In a study that was conducted by Fujita et al., it was reported that the hepcidin-to-ferritin ratio showed a significant decrease in patients with HCV when compared to controls or HBV patients [99]. In vitro, conflicting results have been generated concerning the antiviral role of iron (Fe). In addition, the use of human hepatocyte cell lines has revealed that iron (Fe) could either cause an enhancement or an inhibition of the HCV replication [99,100]. The mechanism of action and expression of hepcidin is illustrated in Figure 3.

2.1.4. Copper (Cu)

The role that copper (Cu) plays in liver disorders can be recognized in Wilson’s disease, due to the tendency for copper (Cu) to accumulate, hence leading to the generation of cellular reactive oxygen species [101,102]. In mammalian cells, ceruloplasmin, cytochrome-c oxidase, hephaestin and copper-zinc superoxide dismutase are cuproenzymes that depend on the availability of copper (Cu) to function properly and to be metabolized [103]. A deficiency in the serum levels of copper (Cu) results in an iron (Fe) overload, cytopenia, tissue fibrosis and an increase in the susceptibility to various infections [102,103].
Acute HCV infection was shown to increase serum copper (Cu), which is then exacerbated in patients with CHC and fibrotic liver disease [6]. Hepatic copper (Cu) levels were shown to increase in patients with CHC, as it binds to MTs (Cu–MTs), hence, leading to hepatic copper (Cu) overload [4]. Cu–MTs were shown to cause a stimulation of the hydroxyl radical generation in rat models, which results in liver damage and, in some cases, fibrosis. As copper (Cu) can be solely excreted in the bile, HCV-mediated inhibition of the secretion of bile acid may cause a retention of the biliary copper (Cu) [38,104].
Remarkably, the metabolism of copper (Cu) and zinc (Zn) has been shown to take place in the liver. Studies have reported that over-supplementation of zinc (Zn) could result in a copper (Cu) deficiency due to the inhibition of the copper (Cu) absorption in the gut [4]. Excess amounts of copper (Cu) upon inflammation increases oxidative stress, and a high Cu/Zn ratio was observed in chronic inflammatory diseases, infections, as well as malnutrition [105]. It can be concluded that copper (Cu) in its different forms can show antiviral properties [106].
Particularly, cuprous oxide nanoparticles (CO-NPs) [106,107], have been shown to cause an inhibition of the HCV cell cultures infectivity at a non-cytotoxic concentration [108,109].

2.2. The Roles and Mechanism of Trace Elements in COVID-19

Drugs repurposing strategy has been shown to have a positive impact on the immune response and it is now widely applied in the COVID-19 pandemic [110]. The adjuvant supply of some important micronutrients that function as positive modulators in the immune system were shown to provide a further support to this strategy, in which some vitamins, such as vitamin A, B6, B12, C, D and E, as well as some essential trace elements, including zinc (Zn), iron (Fe), selenium (Se) and copper (Cu), were considered promising [25]. However, currently, the database is still very limited, and it is not yet confirmed whether some trace elements or vitamins are certainly deficient in COVID-19 patients and whether their serum concentrations are linked to the severity of the disease or to the mortality risk [48].

2.2.1. Zinc (Zn)

As mentioned previously, zinc (Zn) has a role in the modulation of antiviral immunity, which affects the inflammatory response in both humans and animals. Information provided by the current clinical studies has shown that modulating Zn status may be crucial to patients with COVID-19 [47]. In coronavirus, zinc (Zn) was shown to inhibit replicase polyproteins proteolytic processing along with inhibiting the activity of RNA-dependent RNA polymerase (RdRp) [42].
A study reported that giving a high-dose intravenous zinc (HDIVZn) can provide protection to various body organs, such as the heart, liver and kidneys against hypoxic damage [43]. It was observed that elderly people are the most vulnerable group to develop severe COVID-19. Among the factors that have been considered is the weakening of the immune system that is related to the old age, which results in a low serum levels of zinc (Zn). In a recent study that was conducted on 3473 patients who have admitted to hospital with a highly severe COVID-19, confirmed that administering zinc (Zn) has a relevant role [111].
Moreover, the same study reported that the patients who were given Zn/ionophore therapy showed a 24% reduced risk of in-hospital mortality, where 17% of those patients who received Zn/ionophore survived while 12% died. Remarkably, the same study reported that patients who were given zinc (Zn) only or the ionophore alone have not shown significant improvement, which suggested that the combination of zinc (Zn) with ionophore have a synergistic action, which could be powerful for elderly patients with COVID-19 [5,41].

2.2.2. Selenium (Se)

In a recent study that was conducted at the Surrey University, China, a statistically strong correlation was observed between the serum concentration of selenium (Se) and the percentages of recovery and fatality in patients with COVID-19. The results demonstrated that the provinces that have high concentrations of selenium (Se) in the soils reported a lower fatality rate from COVID-19 compared to other areas that have selenium (Se)-deficient soils [45].
Selenium (Se) deficiency in patients with COVID-19 was shown to be related to mutations, replication, as well as virulence of RNA viruses. Therefore, selenium (Se) was shown to be helpful to recover the host’s antioxidant ability, decrease in the endotheliocytes apoptosis and damage, as well as a decrease in the thrombocytes aggregation [46]. Furthermore, low selenium (Se) levels were noticed widely in patients with a higher risk of developing a severe COVID-19 infection and, in particular, in senior individuals [47].
Studies have reported that the immune system relies on a number of selenoproteins that contain selenocysteine in the active site and known to be dependent for a full expression and enzymatic activity on the abundant supply of selenium (Se). Thus, selenium (Se) deficiency is considered a risk factor for viral infections [112]. It is worth mentioning that the cure rate from COVID-19 has been recently linked to the basal selenium (Se) status in studies that have been conducted in different areas of China [45]. Together, the available published studies have shown a support to the conception that selenium (Se) may be relevant to SARS-CoV-2 infection and COVID-19 disease course [113]. However, current data on the status of selenium (Se) in individual patients who experience severe COVID-19 symptoms are missing. Thus, it is hypothesized that a severe selenium (Se) deficiency is associated with poor survival rates in COVID-19 [48].

2.2.3. Copper (Cu)

Copper (Cu) plays an important role in the regular immune response. A number of cupro-enzymes were reported to have a direct effect on the general body’s developmental, metabolic and adaptive pathways [14,112]. Years after the first viral pandemic, scientists have estimated the detailed role of copper (Cu) in deactivating various viruses, including coronavirus 229E and COVID-19. William Keevil and his team recently applied copper (Cu) to fight coronavirus, where they have added copper (Cu) elements in a wide range of public places.
COVID-19 was shown to be deactivated by copper (Cu) ions that were applied to the surfaces within few hours only. The mechanism by which these ions deactivated the virus was due to the copper (Cu) ions attacking the virus’s lipid membrane, invading it and, hence destroying its nucleic acids [47]. The antiviral characteristics of copper (Cu) include inactivating the single or double-stranded DNA or RNA viruses, blocking papain-like protease 2, which is crucial for the replication of SARS-CoV-1 and destroying the viral genomes [51].
There are limited clinical data on the serum levels of copper (Cu) in COVID-19 patients. Some clinical studies have focused on pregnant women with COVID-19 and have observed a trimester-dependent increase in serum levels of copper (Cu), with only small deviations as compared to healthy control pregnancies. Remarkably, serum levels of copper (Cu) were shown to increase in pregnant women with COVID-19 particularly in the first and the third trimesters; however, serum levels of copper (Cu) have not been shown to increase in the second trimester [49].
Another recent study that was conducted in Wuhan, China indicated that copper (Cu) serum levels are generally increased in patients with severe COVID-19 infection, and no difference was observed in full blood copper (Cu) as compared to survivors and non-survivors. However, the difference in the serum concentrations of copper (Cu) related to the severity of COVID-19 was small [20]. Recently, it was reported that an increased oxidative stress and an elevation in the lipid peroxide levels were detected in patients with COVID-19 who also experience severe pneumonia and presented with a particular increase in the copper-to-zinc ratio and a drop in the levels of circulating antioxidants, such as vitamin C, selenium (Se), thiol proteins and glutathione [18]. In a study that was conducted by Lee et al., an assessment of the serum concentrations of a number of trace elements along with an evaluation of their clinical significance in a number of critically ill patients was conducted.
A decrease in copper (Cu) concentrations was seen at ICU admission. An increase in copper (Cu) levels with its substitution for the duration of the ICU stay was associated with a significant decrease in mortality as compared to lower concentration of copper (Cu) (5.6 vs. 50.0%, p ¼ 0.013) [50]. Other studies have reported that copper (Cu) supplementation has an important role in regulating IL-2, which has a critical role in the proliferation of T helper cell, the Th1 and Th2 cells balance and, the cytotoxicity of natural killer (NK) cell, which altogether have important roles in managing the immune dysregulation in critically ill COVID-19 patients [51].
A closer understanding of the signalling of copper (Cu), its vulnerability, assessment and interpretation methods, rout of administration as well as dosages are all needed to be taken into consideration regarding the therapeutic administration of copper (Cu) as part of treating critically ill COVID-19 patients. Increased attention has to be given to avoid copper (Cu) toxic limits and further work is still required to estimate the adverse effects of different copper (Cu) doses [114,115].

2.2.4. Iron (Fe)

Iron (Fe) is an essential trace element that was proven to play vital roles in both eukaryotic and prokaryotic cells [116]. Several studies were conducted to assess the regulation of iron (Fe) in the defence mechanism of host cells, where they demonstrated that a decrease in the levels of iron (Fe) will lead to resistance against viral infections [117], whereas an increased level of iron (Fe) was shown to expand the virus population [118]. Recently, many studies have been conducted to analyse the status of iron in COVID-19 prognosis. In a study, it was found that the serum levels of iron (Fe) have decreased in confirmed SARS patients [119].
Other studies on COVID-19 have revealed that a decreased level of serum iron (Fe) was considered an independent risk factor for developing severe hypoxemic respiratory failure and further death in patients who had COVID-19 [120]. Moreover, an increased level of serum ferritin was found to be related to poor outcomes in COVID-19 patients [121]. A number of studies have recently demonstrated that the levels of serum ferritin in COVID-19 non-survivors have exceeded the serum ferritin levels in the survivors by two-folds.
However, it is still unclear whether hyper-ferritinemia in COVID-19 patients is a systemic marker or a modulator in disease pathogenesis. Increasing evidence has shown that oxidative stress, inflammatory conditions as well as changes in the iron (Fe) homeostasis are linked at a systemic level [122,123]. Iron (Fe) deficiency has been shown to be associated with weakened skeletal muscles and may cause a reduction in the respiratory capacity. As a result, this may worsen the COVID-19 patient’s condition and hence leads to death [124].
In a recent study that was conducted in Turkey to determine vitamin B12, vitamin D, folate and iron (Fe) levels in patients with COVID-19, it was reported that the serum levels of iron (Fe) were low. The results have also shown that that a deficiency in the serum levels of iron (Fe), vitamin D and folate and excess levels of vitamin B12, were correlated with ICU hospitalization, intubation and death [125]. Nevertheless, iron (Fe) supplementation was shown to enhance the immunity; however, it was also reported that iron can exacerbate the infection [126].
Studies that analysed SARS-CoV-1 and MERS-CoV have suggested that iron (Fe) plays a vital role in the replication of the virus [63]. In a study that was conducted by Augustine et al., it was found that oral iron (Fe) supplementation given to a patient who has an inflammatory condition might lead to oxidative stress and hence adverse gut microbiome [127]. This has raised the concerns regarding whether iron (Fe) supplementation programs are safe and effective during COVID-19 pandemic [128].
Kell et al. recently suggested that a lactoferrin supplementation could enhance the immunity, reduce inflammation and modulate the production of cytokine and ROS, which all result in a reduction in the iron (Fe) overload, due to the immunomodulatory and anti-inflammatory effects of lactoferrin and its ability to bind to different receptors especially the ones targeted by coronaviruses, hence, blocking their entry into the host cell [129].

3. Roles and Mechanism of Micronutrients in Diabetes Mellitus

Type-2 Diabetes Mellitus (T2DM) is affected by a mixture of both internal and external risk factors. Most studies have focused on studying the status of macronutrients as a strategy for preventing T2DM. On the other hand, micronutrients and, in particular, some trace elements (TEs) were proposed in various studies as determinants of T2DM risk [130]. Particularly, the imbalanced levels of chromium (Cr), zinc (Zn), vanadium (V), copper (Cu), selenium (Se) and iron (Fe) seem to have a role in the development and progression of T2DM [26].
Recent studies have reported that the overload or deficiency of trace elements could be related to oxidative stress, which is associated with insulin resistance and hence diabetes [131]. Additionally, chromium, zinc, copper, iron and selenium have been observed in many studies to have an antioxidant effect and might lead to an enhancement in the insulin action by activating insulin receptor sites or increasing insulin sensitivity [26]. In this section, the roles and mechanisms of two trace elements, zinc (Zn) and selenium (Se) and the electrolyte magnesium (Mg) are discussed.

3.1. Zinc (Zn)

Zinc (Zn) has been reported in many studies to have a distinctive role in the regulation of glycaemic control due to its antioxidant characteristics. The mechanisms by which zinc (Zn) achieves this action are the stimulation of glycolysis, decreasing gluconeogenesis and the inhibition of the activity of alpha-glucosidase in the intestine [30]. Studies that used animal models to analyse and evaluate the role of zinc (Zn) in diabetes progression have revealed that zinc (Zn) has shown a consistent role in the insulin secretion while improving the sensitivity of insulin [132]. Other studies have also reported the roles that zinc (Zn) plays to regulate the hepatic insulin clearance [133].
However, clinical studies have shown inconsistent results [134]. A study that was conducted on Finnish men reported higher serum levels of zinc (Zn) to be associated with an increased T2DM risk [52]. However, another study that was conducted on older prediabetic Australian men reported higher serum levels of zinc (Zn) to be associated with a decreased insulin resistance [53]. Other randomized controlled studies have revealed some beneficial effects of zinc (Zn) supplementation given to diabetic patients for glycemic control [30].
Pancreatic β cells were shown to have a high concentration of zinc (Zn) when compared to other cells types. Particularly, insulin secretory granules were shown to contain the highest amount of zinc (Zn) within the pancreatic β cells [54]. In T2DM, due to the antioxidative role of zinc (Zn), studies have shown that lacking zinc (Zn) could lead to the damage of pancreatic β cells following oxidative stress. In a prospective cohort study that was recently conducted in the United States, 82,000 women were analysed, and results have revealed that low zinc (Zn) intake have resulted in a 17% increase in the risk of developing diabetes when compared to other women who took sufficient amounts of zinc (Zn) [135]. In a recent study that was conducted in China, a negative correlation between plasma concentrations of zinc (Zn) and the onset of diabetes was reported [55]. Although these data have suggested that providing zinc (Zn) supplementation will prevent the glucose homeostasis disruption in zinc-deficient patients, further studies should be conducted for clarifying the role that zinc (Zn) supplementation play to prevent the onset of diabetes. On the other hand, it is worth mentioning that over-supplementation of zinc (Zn) may lead to deleterious effects, due to the unfavourable increase in the levels of HbA1c and high blood pressure [54].

3.2. Selenium (Se)

As mentioned in previous section, selenoproteins have antioxidant and anti-inflammatory properties [136], which suggests the beneficial effects of selenium (Se) for patients with T2DM as it is characterized by oxidative stress. Selenium (as selenate) was shown to have anti-diabetic, as well as insulin-mimetic properties, at high doses [56]. However, the observational epidemiological studies have shown that higher plasma concentration of selenium (Se) was associated with a higher T2DM occurrence [57], which leaves the role of selenium (Se) in diabetes a matter of discussion [59,122,123,124].
Many studies have conducted different assessments to figure out the relationship between the plasma levels of selenium (Se) and the common conditions that involve an increased oxidative stress and inflammatory reaction, such as T2DM [137,138,139]. A small randomized controlled trial (RCT) was conducted in the United States and showed that the administration of 200 μg/day of selenium (Se) for preventing non-melanoma skin cancer, resulted in an incidence of T2DM in patients who were reported with the highest selenium (Se) intake at baseline [140]. Several recent studies have given biological plausibility for a diabetogenic effect of selenium (Se) and selenoproteins [61]. Moreover, studies are also showing that minimized levels of environmental risk factors, such as trace elements dietary intake as well as exposure to contaminants, can affect diabetes aetiology [141].
Therefore, the chemical exposome as well as obesity, lifestyle and diabetic family history may be among the factors to be considered as additional determinants of this metabolic disease [142]. Recent experimental to epidemiologic studies have suggested a positive relationship between selenium (Se) and the higher risk of diabetes; however, the majority of these studies were conducted among prevalent cases, rendering it hard to confirm in a diabetes case whether selenium (Se) is the cause or the result [143,144].

3.3. Magnesium (Mg)

Magnesium (Mg) is the rate-limiting factor for a number of enzymes that are involved in the metabolism of carbohydrate and energy, as well as being essential for the intermediary metabolism to synthesize macromolecules [145]. Magnesium (Mg) deficiency has been frequently reported in obese subjects [58], and is observed in diabetic patients or in those with metabolic syndromes. Magnesium (Mg) deficiency has also been reported to increases the risk for T2DM [59]. Magnesium (Mg) depletion was shown to promote direct and indirect chronic inflammation by the modification of the intestinal microbiota [146]. T2DM has also been shown to be characterized with an altered homeostasis of magnesium (Mg), and results of the studies conducted have shown an inverse relationship between magnesium (Mg) intake and the risk of developing T2DM in a dose-response manner [60]. A recent epidemiologic study has shown a high prevalence of hypomagnesemia in type-2 diabetic subjects [61].
Another recent study revealed that depletion of magnesium (Mg) in type-2 diabetic patients is mainly a consequence of a low magnesium (Mg) intake in addition to the increased magnesium (Mg) urinary loss, as a result of an impaired renal function [147]. Recent studies have demonstrated that hypomagnesemia was associated with the development of T2DM. The influence of magnesium (Mg) on the metabolism of glucose, insulin action and sensitivity, may give an explanation to the negative association between T2DM incidence and magnesium (Mg) intake [148,149]. The relationship between magnesium (Mg) and insulin signalling and resistance is illustrated in Figure 4.
Other studies have suggested that magnesium (Mg) deficiency could have other contributions to the progression of T2DM, such as modulating Na+/K+—ATPase, which is crucial for the maintenance of the membrane potential and low concentration of cytoplasmic sodium [150]. Studies suggested that the deficiency in magnesium (Mg) may not be a secondary consequence of T2DM; however, it may be play a role in insulin resistance and altering glucose tolerance, thus leading to the development of T2DM [151].

4. Current Status and Clinical Trials

Table 2 summarizes a number of clinical trials and their current status in hepatitis, covid19 and type-2 diabetes mellitus and the roles of the trace elements zinc (Zn), slelenium (Se), copper (Cu) and iron (Fe) and the electrolyte magnesium (Mg) whenever applicable [152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170].

5. Conclusions

Several studies have been conducted to assess the roles of certain vitamins and trace elements in coping with viral infections and other chronic diseases. The essential trace elements, such as copper (Cu), selenium (Se), zinc (Zn), iron (Fe) and the electrolyte magnesium (Mg), are among the most commonly studied micronutrients. Studies have reported that an impaired homeostasis of these trace elements may lead to inflammatory changes and/or metabolic abnormalities.
Zinc (Zn), selenium (Se), copper (Cu) and iron (Fe) have been studied for their involvement in the liver pathology, in particular, chronic hepatitis. Several studies have been conducted in the last decade to assess the roles and mechanisms of these trace elements in hepatic disorders. Moreover, extensive studies have focused on analysing zinc (Zn), selenium (Se) and copper (Cu) for their antiviral activities against SARS-CoV2 virus; however, the current database available remains limited, and it is not yet confirmed whether some trace elements or vitamins are certainly deficient in COVID-19 patients or whether their serum concentrations are linked to the disease severity or to the mortality risk.
Additionally, Cr, Zn, Cu, Fe and Se have been observed in many studies to have an antioxidant effect and might lead to enhancement in the insulin action by activating insulin receptor sites or increasing insulin sensitivity. However, it is worth mentioning that over-supplementation of some of these trace elements, for instance zinc (Zn), may lead to deleterious effects due to the unfavourable increase in the levels of HbA1c and high blood pressure. Recent advances in newly discovered molecular biological techniques have facilitated the discovery of the novel mechanisms by which an impairment in the metabolism of these trace elements causes different metabolic abnormalities. Further studies are still required for assessment of the dosing and toxicity of these trace elements.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

CHCChronic hepatitis C
CO-NPsCoprous oxide nanoparticles
COVIDCoronavirus disease
CuCopper
DAADirect acting antiviral
DPPDiabetes prevention program
FeIron
GPX1Glutathione peroxidase-1
H1N1Human influenza
HBVHepatitis B Virus
HCVHepatitis C Virus
HDIVZnHigh dose intravenous zinc
HEVHepatitis E Virus
HuhHuman hepatoma
hZAPHuman zinc finger antiviral protein
ICUIntensive care unit
IFNInterferon
ILInterleukin
MgMagnesium
mRNAMessenger ribonucleic acid
MTMetallothionein
NK cellNatural killer cell
pgRNAPregenomic ribonucleic acid
RCTRandomized controlled trial
RdRpRNA-dependent RNA polymerase
ROSReactive oxygen species
SeSelenium
SELENOPSelenoproteins
T2DMType-2 diabetes mellitus
TEsTrace elements
TH cellT helper cell
TXNRDThioredoxin reductase
ZnZinc

References

  1. Bhattacharya, P.T.; Misra, S.R.; Hussain, M. Nutritional Aspects of Essential Trace Elements in Oral Health and Disease: An Extensive Review. Scientifica 2016, 2016, 5464373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Attar, T. A Mini-Review on Importance and Role of Trace Elements in the Human Organism. Chem. Rev. Lett. 2020, 3, 117–130. [Google Scholar]
  3. Şahin, M.; Karayakar, F.; Erdogan, K.E.; Bas, F.; Colak, T. Liver Tissue Trace Element Levels in HepB Patients and the Relationship of These Elements with Histological Injury in the Liver and with Clinical Parameters. J. Trace Elem. Med. Biol. 2018, 45, 70–77. [Google Scholar] [CrossRef]
  4. Gupta, S.; Read, S.A.; Shackel, N.A.; Hebbard, L.; George, J.; Ahlenstiel, G. The Role of Micronutrients in the Infection and Subsequent Response to Hepatitis C Virus. Cells 2019, 8, 603. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Hang, X.; Peng, H.; Song, H.; Qi, Z.; Miao, X.; Xu, W. Antiviral Activity of Cuprous Oxide Nanoparticles against Hepatitis C Virus in Vitro. J. Virol. Methods 2015, 222, 150–157. [Google Scholar] [CrossRef]
  6. Guo, C.H.; Chen, P.C.; Ko, W.S. Status of Essential Trace Minerals and Oxidative Stress in Viral Hepatitis C Patients with Nonalcoholic Fatty Liver Disease. Int. J. Med. Sci. 2013, 10, 730–737. [Google Scholar] [CrossRef] [Green Version]
  7. Kaushik, N.; Subramani, C.; Anang, S.; Muthumohan, R.; Shalimar Nayak, B.; Ranjith-Kumar, C.T.; Surjit, M. Crossm Zinc Salts Block Hepatitis E Virus. J. Virol. 2017, 91, e00754-17. [Google Scholar]
  8. Kumar, A.; Kubota, Y.; Chernov, M.; Kasuya, H. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. Med. Hypotheses 2020, 144, 109848. [Google Scholar] [CrossRef]
  9. Chasapis, C.T.; Georgiopoulou, A.K.; Perlepes, S.P.; Bjørklund, G.; Peana, M. A SARS-CoV-2 -human metalloproteome interaction map. J. Inorg. Biochem. 2021, 219, 111423. [Google Scholar] [CrossRef]
  10. Andreou, A.; Trantza, S.; Filippou, D.; Filippou, D.; Sipsas, N.; Tsiodras, S. COVID-19: The Potential Role of Copper and N-Acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments against SARS-CoV-2. In Vivo (Brooklyn) 2020, 34, 1567–1588. [Google Scholar] [CrossRef]
  11. Gattermann, N.; Muckenthaler, M.U.; Kulozik, A.E.; Metzgeroth, G.; Hastka, J. Investigation of Iron Deficiency and Iron Overload. Dtsch. Arztebl. Int. 2021, 118, 847–856. [Google Scholar] [CrossRef] [PubMed]
  12. Ivanova, I.D.; Pal, A.; Simonelli, I.; Atanasova, B.; Ventriglia, M.; Rongioletti, M.; Squitti, R. Evaluation of Zinc, Copper, and Cu:Zn Ratio in Serum, and Their Implications in the Course of COVID-19. J. Trace Elem. Med. Biol. 2022, 71, 126944. [Google Scholar] [CrossRef] [PubMed]
  13. Hackler, J.; Heller, R.A.; Sun, Q.; Schwarzer, M.; Diegmann, J.; Bachmann, M.; Moghaddam, A.; Schomburg, L. Relation of Serum Copper Status to Survival in COVID-19. Nutrients 2021, 13, 1898. [Google Scholar] [CrossRef] [PubMed]
  14. Asprouli, E.; Kalafati, I.P.; Sakellari, A.; Karavoltsos, S.; Vlachogiannakos, J.; Revenas, K.; Kokkinos, A.; Dassenakis, M.; Dedoussis, G.V.; Kalogeropoulos, N. Evaluation of Plasma Trace Elements in Different Stages of Nonalcoholic Fatty Liver Disease. Biol. Trace Elem. Res. 2019, 188, 326–333. [Google Scholar] [CrossRef]
  15. Parlakgül, G.; Arruda, A.P.; Pang, S.; Cagampan, E.; Min, N.; Güney, E.; Lee, G.Y.; Inouye, K.; Hess, H.F.; Xu, C.S.; et al. Regulation of Liver Subcellular Architecture Controls Metabolic Homeostasis. Nature 2022, 603, 736–742. [Google Scholar] [CrossRef] [PubMed]
  16. Kozeniecki, M.; Ludke, R.; Kerner, J.; Patterson, B. Micronutrients in Liver Disease: Roles, Risk Factors for Deficiency, and Recommendations for Supplementation. Nutr. Clin. Pract. 2020, 35, 50–62. [Google Scholar] [CrossRef] [Green Version]
  17. Zhu, L.C.; Chen, X.J.; Kong, X.; Cai, Y.D. Investigation of the Roles of Trace Elements during Hepatitis C Virus Infection Using Protein-Protein Interactions and a Shortest Path Algorithm. Biochim. Biophys. Acta—Gen. Subj. 2016, 1860, 2756–2768. [Google Scholar] [CrossRef]
  18. Pincemail, J.; Cavalier, E.; Charlier, C.; Cheramy–bien, J.P.; Brevers, E.; Courtois, A.; Fadeur, M.; Meziane, S.; Goff, C.L.; Misset, B.; et al. Oxidative Stress Status in COVID-19 Patients Hospitalized in Intensive Care Unit for Severe Pneumonia. A Pilot Study. Antioxidants 2021, 10, 257. [Google Scholar] [CrossRef]
  19. Nedić, O.; Šunderić, M.; Robajac, D.; Miljuš, G.; Četić, D.; Penezić, A. Major Trace Elements and Their Binding Proteins in the Early Phase of COVID-19 Infection. J. Biol. Inorg. Chem. 2022, 27, 261–269. [Google Scholar] [CrossRef]
  20. Zeng, H.L.; Yang, Q.; Yuan, P.; Wang, X.; Cheng, L. Associations of Essential and Toxic Metals/Metalloids in Whole Blood with Both Disease Severity and Mortality in Patients with COVID-19. FASEB J. 2021, 35, 1–12. [Google Scholar] [CrossRef]
  21. De Jesus, J.R.; De Araújo Andrade, T. Understanding the Relationship between Viral Infections and Trace Elements from a Metallomics Perspective: Implications for COVID-19. Metallomics 2020, 12, 1912–1930. [Google Scholar] [CrossRef] [PubMed]
  22. Fooladi, S.; Matin, S.; Mahmoodpoor, A. Copper as a Potential Adjunct Therapy for Critically Ill COVID-19 Patients. Clin. Nutr. ESPEN 2020, 40, 90–91. [Google Scholar] [CrossRef] [PubMed]
  23. Nedjimi, B. Can Trace Element Supplementations (Cu, Se, and Zn) Enhance Human Immunity against COVID-19 and Its New Variants? Beni-Suef Univ. J. Basic Appl. Sci. 2021, 10, 33. [Google Scholar] [CrossRef] [PubMed]
  24. Taheri, M.; Bahrami, A.; Habibi, P.; Nouri, F. A Review on the Serum Electrolytes and Trace Elements Role in the Pathophysiology of COVID-19. Biol. Trace Elem. Res. 2021, 199, 2475–2481. [Google Scholar] [CrossRef] [PubMed]
  25. Calder, P.C.; Carr, A.C.; Gombart, A.F.; Eggersdorfer, M. Reply to “Comment on: Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. Nutrients 2020, 12, 1181”. Nutrients 2020, 12, 2326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Rodríguez-Pérez, C.; Gómez-Peña, C.; Pérez-Carrascosa, F.M.; Vrhovnik, P.; Echeverría, R.; Salcedo-Bellido, I.; Mustieles, V.; Željka, F.; Arrebola, J.P. Trace Elements Concentration in Adipose Tissue and the Risk of Incident Type 2 Diabetes in a Prospective Adult Cohort. Environ. Pollut. 2021, 286, 117496. [Google Scholar] [CrossRef]
  27. Himoto, T.; Masaki, T. Current Trends of Essential Trace Elements in Patients with Chronic Liver Diseases. Nutrients 2020, 12, 2084. [Google Scholar] [CrossRef]
  28. Siddiqui, K.; Bawazeer, N.; Scaria Joy, S. Variation in Macro and Trace Elements in Progression of Type 2 Diabetes. Sci. World J. 2014, 2014, 461591. [Google Scholar] [CrossRef] [Green Version]
  29. The National Diabetes Prevention Program (NDPP). The Diabetes Prevention Program (DPP). Diabetes Care 2002, 25, 2165–2171. [Google Scholar] [CrossRef] [Green Version]
  30. Kant, R.; Verma, V.; Patel, S.; Chandra, R.; Chaudhary, R.; Shuldiner, A.R.; Munir, K.M. Effect of Serum Zinc and Copper Levels on Insulin Secretion, Insulin Resistance and Pancreatic β Cell Dysfunction in US Adults: Findings from the National Health and Nutrition Examination Survey (NHANES) 2011–2012. Diabetes Res. Clin. Pract. 2021, 172, 108627. [Google Scholar] [CrossRef]
  31. Yousaf, T.; Sun, Y.; Naz, W.; Liu, Y.; Xu, J.; Yuan, S.; Wu, K.; Wang, M.; Wang, J.; Guo, M.; et al. Multiomics Analysis of Endocytosis upon HBV Infection and Identification of SCAMP1 as a Novel Host Restriction Factor against HBV Replication. Int. J. Mol. Sci. 2022, 23, 2211. [Google Scholar] [CrossRef] [PubMed]
  32. Mao, R.; Nie, H.; Cai, D.; Zhang, J.; Liu, H.; Yan, R.; Cuconati, A.; Block, T.M.; Guo, J.T.; Guo, H. Inhibition of Hepatitis B Virus Replication by the Host Zinc Finger Antiviral Protein. PLoS Pathog. 2013, 9, e1003494. [Google Scholar] [CrossRef] [PubMed]
  33. Kuwano, A.; Yada, M.; Nagasawa, S.; Tanaka, K.; Morita, Y.; Masumoto, A.; Motomura, K. Serum α-Fetoprotein Level at Treatment Completion Is a Useful Predictor of Hepatocellular Carcinoma Occurrence More than One Year after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment. J. Viral Hepat. 2022, 29, 35–42. [Google Scholar] [CrossRef] [PubMed]
  34. Dai, H.; Wang, L.; Li, L.; Huang, Z.; Ye, L. Metallothionein 1: A New Spotlight on Inflammatory Diseases. Front. Immunol. 2021, 12, 13–21. [Google Scholar] [CrossRef]
  35. Xq, W.; Cm, L.; Chen, L.; Ck, C.; Zf, Y.; Yx, C. Selenium Levels in Patients with Hepatitis C Virus-Related Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma: A Pilot Study. Hepatology 2013, 57, 2543–2544. [Google Scholar] [CrossRef]
  36. Petrović, S.; Maletić, M.; Lakić, N.; Aleksić, N.; Maletić, J.; Ristanić, M.; Stanimirović, Z. The Effects of Antioxidants Provided with Feed on Certain Quality Parameters of Bull Semen under Heat Stress Conditions. Acta Vet. 2021, 70, 453–470. [Google Scholar] [CrossRef]
  37. Wei, Y.; Ye, W.; Zhao, W. Serum Iron Levels Decreased in Patients with HBV-Related Hepatocellular Carcinoma, as a Risk Factor for the Prognosis of HBV-Related HCC. Front. Physiol. 2018, 9, 66. [Google Scholar] [CrossRef] [Green Version]
  38. Gao, Y.H.; Wang, J.Y.; Liu, P.Y.; Sun, J.; Wang, X.M.; Wu, R.H.; He, X.T.; Tu, Z.K.; Wang, C.G.; Xu, H.Q.; et al. Iron Metabolism Disorders in Patients with Hepatitis B-Related Liver Diseases. World J. Clin. Cases 2018, 6, 600–610. [Google Scholar] [CrossRef]
  39. Yang, Y.M.; Cho, Y.E.; Hwang, S. Crosstalk between Oxidative Stress and Inflammatory Liver Injury in the Pathogenesis of Alcoholic Liver Disease. Int. J. Mol. Sci. 2022, 23, 774. [Google Scholar] [CrossRef]
  40. Cao, X.L.; Zhao, M.F.; Li, D.G.; Xing, Y.; Zhang, Y.C.; Chen, J.; He, X.Y.; Cui, R.; Meng, J.X.; Xiao, X.; et al. Establishment of Macrophage Model of Iron Overload in Vitro and the Injury Induced by Oxidative Stress on Macrophage with Iron Overload. Zhonghua Yi Xue Za Zhi 2016, 96, 129–133. [Google Scholar]
  41. Tao, T.Y.; Gitlin, J.D. Hepatic Copper Metabolism: Insights from Genetic Disease. Hepatology 2003, 37, 1241–1247. [Google Scholar] [CrossRef] [PubMed]
  42. Read, S.A.; Obeid, S.; Ahlenstiel, C.; Ahlenstiel, G. The Role of Zinc in Antiviral Immunity. Adv Nutr. 2019, 10, 696–710. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Cheung, E.; Nikfarjam, M.; Jackett, L.; Bolton, D.M.; Ischia, J.; Patel, O. The Protective Effect of Zinc Against Liver Ischaemia Reperfusion Injury in a Rat Model of Global Ischaemia. J. Clin. Exp. Hepatol. 2020, 10, 228–235. [Google Scholar] [CrossRef] [PubMed]
  44. Frontera, J.A.; Rahimian, J.O.; Yaghi, S.; Liu, M.; Lewis, A.; De Havenon, A.; Mainali, S.; Huang, J.; Scher, E.; Wisniewski, T.; et al. Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study. Res. Sq. 2020, rs-3. [Google Scholar] [CrossRef]
  45. Zhang, J.; Taylor, E.W.; Bennett, K.; Saad, R.; Rayman, M.P. Association between Regional Selenium Status and Reported Outcome of COVID-19 Cases in China. Am. J. Clin. Nutr. 2020, 111, 1297–1299. [Google Scholar] [CrossRef]
  46. Hiffler, L.; Rakotoambinina, B. Selenium and RNA Virus Interactions: Potential Implications for SARS-CoV-2 Infection (COVID-19). Front. Nutr. 2020, 7, 164. [Google Scholar] [CrossRef]
  47. Ermakov, V.V.; Jovanović, L.N. Biological Role of Trace Elements and Viral Pathologies. Geochem. Int. 2022, 60, 137–153. [Google Scholar] [CrossRef]
  48. Moghaddam, A.; Heller, R.A.; Sun, Q.; Seelig, J.; Cherkezov, A.; Seibert, L.; Hackler, J.; Seemann, P.; Diegmann, J.; Pilz, M.; et al. Selenium Deficiency Is Associated with Mortality Risk from COVID-19. Nutrients 2020, 12, 2098. [Google Scholar] [CrossRef]
  49. Anuk, A.T.; Polat, N.; Akdas, S.; Erol, S.A.; Tanacan, A.; Biriken, D.; Keskin, H.L.; Moraloglu Tekin, O.; Yazihan, N.; Sahin, D. The Relation Between Trace Element Status (Zinc, Copper, Magnesium) and Clinical Outcomes in COVID-19 Infection During Pregnancy. Biol. Trace Elem. Res. 2021, 199, 3608–3617. [Google Scholar] [CrossRef]
  50. Lee, Y.H.; Bang, E.S.; Lee, J.H.; Lee, J.D.; Kang, D.R.; Hong, J.; Lee, J.M. Serum Concentrations of Trace Elements Zinc, Copper, Selenium, and Manganese in Critically Ill Patients. Biol. Trace Elem. Res. 2019, 188, 316–325. [Google Scholar] [CrossRef] [Green Version]
  51. Raha, S.; Mallick, R.; Basak, S.; Duttaroy, A.K. Is Copper Beneficial for COVID-19 Patients? Med. Hypotheses 2020, 142, 109814. [Google Scholar] [CrossRef] [PubMed]
  52. Yary, T.; Virtanen, J.K.; Ruusunen, A.; Tuomainen, T.P.; Voutilainen, S. Serum Zinc and Risk of Type 2 Diabetes Incidence in Men: The Kuopio Ischaemic Heart Disease Risk Factor Study. J. Trace Elem. Med. Biol. 2016, 33, 120–124. [Google Scholar] [CrossRef] [PubMed]
  53. Vashum, K.P.; McEvoy, M.; Milton, A.H.; Islam, M.R.; Hancock, S.; Attia, J. Is Serum Zinc Associated with Pancreatic Beta Cell Function and Insulin Sensitivity in Pre-Diabetic and Normal Individuals? Findings from the Hunter Community Study. PLoS ONE 2014, 9, e83944. [Google Scholar] [CrossRef] [Green Version]
  54. Fukunaka, A.; Fujitani, Y. Role of Zinc Homeostasis in the Pathogenesis of Diabetes and Obesity. Int. J. Mol. Sci. 2018, 19, 476. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Shan, Z.; Bao, W.; Zhang, Y.; Rong, Y.; Wang, X.; Jin, Y.; Song, Y.; Yao, P.; Sun, C.; Hu, F.B.; et al. Interactions between Zinc Transporter-8 Gene (SLC30A8) and Plasma Zinc Concentrations for Impaired Glucose Regulation and Type 2 Diabetes. Diabetes 2014, 63, 1796–1803. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Steinbrenner, H. Interference of Selenium and Selenoproteins with the Insulin-Regulated Carbohydrate and Lipid Metabolism. Free Radic. Biol. Med. 2013, 65, 1538–1547. [Google Scholar] [CrossRef] [PubMed]
  57. Rayman, M.P.; Stranges, S. Epidemiology of Selenium and Type 2 Diabetes: Can We Make Sense of It? Free Radic. Biol. Med. 2013, 65, 1557–1564. [Google Scholar] [CrossRef]
  58. De Baaij, J.H.F.; Hoenderop, J.G.J.; Bindels, R.J.M. Magnesium in Man: Implications for Health and Disease. Physiol. Rev. 2015, 95, 1–46. [Google Scholar] [CrossRef]
  59. Von Ehrlich, B.; Barbagallo, M.; Classen, H.G.; Guerrero-Romero, F.; Mooren, F.C.; Rodriguez-Moran, M.; Vierling, W.; Vormann, J.; Kisters, K. Significance of Magnesium in Insulin Resistance, Metabolic Syndrome, and Diabetes—Recommendations of the Association of Magnesium Research e.V. Trace Elem. Electrolytes 2017, 34, 124–129. [Google Scholar] [CrossRef]
  60. Bertinato, J.; Wang, K.C.; Hayward, S. Serum Magnesium Concentrations in the Canadian Population and Associations with Diabetes, Glycemic Regulation, and Insulin Resistance. Nutrients 2017, 9, 296. [Google Scholar] [CrossRef]
  61. Lee, Y.S.; Olefsky, J. Chronic Tissue Inflammation and Metabolic Disease. Genes Dev. 2021, 35, 307–328. [Google Scholar] [CrossRef] [PubMed]
  62. Grubaugh, N.D.; Ladner, J.T.; Lemey, P.; Pybus, O.G.; Rambaut, A.; Holmes, E.C.; Andersen, K.G. Tracking Virus Outbreaks in the Twenty-First Century. Nat. Microbiol. 2019, 4, 10–19. [Google Scholar] [CrossRef] [PubMed]
  63. Liu, W.; Zhang, S.; Nekhai, S.; Liu, S. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival. Curr. Clin. Microbiol. Rep. 2020, 7, 13–19. [Google Scholar] [CrossRef]
  64. Misumi, I.; Mitchell, J.E.; Lund, M.M.; Cullen, J.M.; Lemon, S.M.; Whitmire, J.K. T Cells Protect against Hepatitis A Virus Infection and Limit Infection-Induced Liver Injury. J. Hepatol. 2021, 75, 1323–1334. [Google Scholar] [CrossRef] [PubMed]
  65. Sahin, M.; Karayakar, F.; Koksal, A.R.; Yetim, A.; İyisoy, M.S.; Şen, İ.; Alkım, H.; Alkım, C.; Colak, T. Changes in Liver Tissue Trace Element Concentrations During Hepatitis B Viral Infection Treatment. Biol. Trace Elem. Res. 2019, 188, 245–250. [Google Scholar] [CrossRef]
  66. Nangliya, V.; Sharma, A.; Yadav, D.; Sunder, S.; Nijhawan, S.; Mishra, S. Study of Trace Elements in Liver Cirrhosis Patients and Their Role in Prognosis of Disease. Biol. Trace Elem. Res. 2015, 1, 35–40. [Google Scholar] [CrossRef]
  67. El-Megharbel, S.M.; Al-Thubaiti, E.H.; Safa, H.; Qahl, R.A.A.-E.; Reham, Z.H. Synthesis and Spectroscopic Characterization of Dapagliflozin/Zn (II), Cr (III) and Se (IV) Novel Complexes That Ameliorate Hepatic Damage, Hyperglycemia and Oxidative Injury Induced by Streptozotocin-Induced Diabetic Male Rats and Their Antibacterial Act. Crystals 2022, 12, 304. [Google Scholar] [CrossRef]
  68. Lin, Y.; He, F.; Lian, S.; Xie, B.; Liu, T.; He, J.; Liu, C. Selenium Status in Patients with Chronic Liver Disease: A Systematic Review and Meta-Analysis. Nutrients 2022, 14, 952. [Google Scholar] [CrossRef]
  69. Diglio, D.C.; Fernandes, S.A.; Stein, J.; Azeredo-da-Silva, A.; De Mattos, A.A.; Tovo, C.V. Role of Zinc Supplementation in the Management of Chronic Liver Diseases: A Systematic Review and Meta-Analysis. Ann. Hepatol. 2020, 19, 190–196. [Google Scholar] [CrossRef]
  70. Coni, P.; Pichiri, G.; Lachowicz, J.I.; Ravarino, A.; Ledda, F.; Fanni, D.; Gerosa, C.; Piras, M.; Coghe, F.; Gibo, Y.; et al. Zinc as a Drug for Wilson’s Disease, Non-Alcoholic Liver Disease and COVID-19-Related Liver Injury. Molecules 2021, 26, 6614. [Google Scholar] [CrossRef]
  71. Miwa, T.; Hanai, T.; Toshihide, M.; Ogiso, Y.; Imai, K.; Suetsugu, A.; Takai, K.; Shiraki, M.; Katsumura, N.; Shimizu, M. Zinc Deficiency Predicts Overt Hepatic Encephalopathy and Mortality in Liver Cirrhosis Patients with Minimal Hepatic Encephalopathy. Hepatol. Res. 2021, 51, 662–673. [Google Scholar] [CrossRef] [PubMed]
  72. Cunha, T.A.; Vermeulen-Serpa, K.M.; Grilo, E.C.; Leite-Lais, L.; Brandão-Neto, J.; Vale, S.H.L. Association between Zinc and Body Composition: An Integrative Review. J. Trace Elem. Med. Biol. 2022, 71, 126940. [Google Scholar] [CrossRef] [PubMed]
  73. Barbara, M.; Mindikoglu, A.L. The Role of Zinc in the Prevention and Treatment of Nonalcoholic Fatty Liver Disease. Metab. Open 2021, 11, 100105. [Google Scholar] [CrossRef]
  74. Grüngreiff, K.; Reinhold, D.; Wedemeyer, H. The Role of Zinc in Liver Cirrhosis. Ann. Hepatol. 2016, 15, 7–16. [Google Scholar] [CrossRef]
  75. Girirajan, S.; Campbell, C.; Eichler, E. EASL Clinical Practice Guidelines on Nutrition in Chronic Liver Disease. Physiol. Behav. 2011, 176, 139–148. [Google Scholar] [CrossRef]
  76. Guo, H.; Jiang, D.; Ma, D.; Chang, J.; Dougherty, A.M.; Cuconati, A.; Block, T.M.; Guo, J.-T. Activation of Pattern Recognition Receptor-Mediated Innate Immunity Inhibits the Replication of Hepatitis B Virus in Human Hepatocyte-Derived Cells. J. Virol. 2009, 83, 847–858. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Uprichard, S.L.; Wieland, S.F.; Althage, A.; Chisari, F.V. Transcriptional and Posttranscriptional Control of Hepatitis B Virus Gene Expression. Proc. Natl. Acad. Sci. USA 2003, 100, 1310–1315. [Google Scholar] [CrossRef] [Green Version]
  78. Kmiec, D.; Lista-Brotos, M.-J.; Ficarelli, M.; Swanson, C.M.; Neil, S.J. The C-Terminal PARP Domain of the Long ZAP Isoform Contributes Essential Effector Functions for CpG-Directed Antiviral Activity. bioRxiv 2021. [Google Scholar] [CrossRef]
  79. Ficarelli, M.; Neil, S.J.D.; Swanson, C.M. Targeted Restriction of Viral Gene Expression and Replication by the ZAP Antiviral System. Annu. Rev. Virol. 2021, 8, 265–283. [Google Scholar] [CrossRef]
  80. Palomo ig Palomo, I.G.; Jaramillo, J.C.; Alarcon, M.L.; Gutierrez, C.L.; Moore-Carrasco, R.; Segovia, F.M.; Leiva, E.M.; Mujica, V.E.; Icaza, G.; Diaz, N.S. Increased Concentrations of Soluble Vascular Cell Adhesion Molecule-1 and Soluble CD40L in Subjects with Metabolic Syndrome. Molecular. Mol. Med. Rep. 2008, 1, 667–671. [Google Scholar] [CrossRef]
  81. Shen, J.; Qi, W.; Dai, J.; Leng, S.; Jiang, K.; Zhang, Y.; Ran, S.; Li, C.; Wen, T. Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma beyond Milan Criteria after Hepatectomy. Chin. Med. J. 2022, 135, 301–308. [Google Scholar] [CrossRef]
  82. Read, S.A.; O’Connor, K.S.; Suppiah, V.; Ahlenstiel, C.L.E.; Obeid, S.; Cook, K.M.; Cunningham, A.; Douglas, M.W.; Hogg, P.J.; Booth, D.; et al. Zinc Is a Potent and Specific Inhibitor of IFN-Λ3 Signalling. Nat. Commun. 2017, 8, 15245. [Google Scholar] [CrossRef] [PubMed]
  83. Kaushik, N.; Anang, S.; Ganti, K.P.; Surjit, M. Zinc: A Potential Antiviral Against Hepatitis e Virus Infection? DNA Cell Biol. 2018, 37, 593–599. [Google Scholar] [CrossRef] [PubMed]
  84. Tang, C.; Li, S.; Zhang, K.; Li, J.; Han, Y.; Zhan, T.; Zhao, Q.; Guo, X.; Zhang, J. Selenium Deficiency-Induced Redox Imbalance Leads to Metabolic Reprogramming and Inflammation in the Liver. Redox Biol. 2020, 36, 101519. [Google Scholar] [CrossRef]
  85. Regina, B.F.; Gladyshev, V.N.; Arnér, E.S.; Berry, M.J.; Bruford, E.A.; Burk, R.F.; Carlson, B.A.; Castellano, S.; Chavatte, L.; Conrad, M.; et al. Selenoprotein Gene Nomenclature. J. Biol. Chem. 2016, 291, 24036–24040. [Google Scholar] [CrossRef] [Green Version]
  86. Guo, Z.; Chen, W.; Dai, G.; Huang, Y. Cordycepin Suppresses the Migration and Invasion of Human Liver Cancer Cells by Downregulating the Expression of CXCR4. Int. J. Mol. Med. 2020, 45, 141–150. [Google Scholar] [CrossRef] [Green Version]
  87. Reja, M.; Makar, M.; Visaria, A.; Marino, D.; Rustgi, V. Increased Serum Selenium Levels Are Associated with Reduced Risk of Advanced Liver Fibrosis and All-Cause Mortality in NAFLD Patients: National Health and Nutrition Examination Survey (NHANES) III. Ann. Hepatol. 2020, 19, 635–640. [Google Scholar] [CrossRef] [PubMed]
  88. Ko, E.; Kim, J.S.; Ju, S.; Seo, H.W.; Chang, Y.; Kang, J.A.; Park, S.G.; Jung, G. Oxidatively Modified Protein-Disulfide Isomerase–Associated 3 Promotes Dyskerin Pseudouridine Synthase 1–Mediated Malignancy and Survival of Hepatocellular Carcinoma Cells. Hepatology 2018, 68, 1851–1864. [Google Scholar] [CrossRef] [Green Version]
  89. Lesnichaya, M.; Karpova, E.; Sukhov, B. Effect of High Dose of Selenium Nanoparticles on Antioxidant System and Biochemical Profile of Rats in Correction of Carbon Tetrachloride-Induced Toxic Damage of Liver. Colloids Surf. B Biointerfaces 2021, 197, 111381. [Google Scholar] [CrossRef]
  90. Morbitzer, M.; Herget, T. Expression of Gastrointestinal Glutathione Peroxidase Is Inversely Correlated to the Presence of Hepatitis C Virus Subgenomic RNA in Human Liver Cells. J. Biol. Chem. 2005, 280, 8831–8841. [Google Scholar] [CrossRef] [Green Version]
  91. Demircan, K.; Bengtsson, Y.; Sun, Q.; Brange, A.; Vallon-Christersson, J.; Rijntjes, E.; Malmberg, M.; Saal, L.H.; Rydén, L.; Borg, Å.; et al. Serum Selenium, Selenoprotein P and Glutathione Peroxidase 3 as Predictors of Mortality and Recurrence Following Breast Cancer Diagnosis: A Multicentre Cohort Study. Redox Biol. 2021, 47, 102145. [Google Scholar] [CrossRef] [PubMed]
  92. Mercer, D.K. Selenium and Viral Infection: Are There Lessons for COVID-19. Br. J. Nutr. 2021, 125, 618–627. [Google Scholar] [CrossRef]
  93. John, R.; Giudicessi, B.A.; Michael, J.; Pantalone, D.W.; Schneider, K.L.; Valentine, S.E.; Simoni, J.M.; Liu-Smith, F.; Pantalone, D.W.; Rood, B.A.; et al. Iron Levels in Hepatocytes and Portal Tract Cells Predict Progression and Outcome of Patients with Advanced Chronic Hepatitis C. AIDS Behav. 2012, 23, 1031–1043. [Google Scholar] [CrossRef]
  94. Milic, S.; Mikolasevic, I.; Orlic, L.; Devcic, E.; Starcevic-Cizmarevic, N.; Stimac, D.; Kapovic, M.; Ristic, S. The Role of Iron and Iron Overload in Chronic Liver Disease. Med. Sci. Monit. 2016, 22, 2144–2151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Rostoker, G.; Vaziri, N.D. Impact of Iatrogenic Iron Overload on the Course of Hepatitis C in the Dialysis Population: A Plea for Caution. Hemodial. Int. 2017, 21, S68–S77. [Google Scholar] [CrossRef] [Green Version]
  96. De Campos, W.N.; Massaro, J.D.; Cançado, E.L.R.; Wiezel, C.E.V.; Simões, A.L.; Teixeira, A.C.; De Souza, F.F.; Mendes-Junior, C.T.; Martinelli, A.D.L.C.; Donadi, E.A. Comprehensive Analysis of HFE Gene in Hereditary Hemochromatosis and in Diseases Associated with Acquired Iron Overload. World J. Hepatol. 2019, 11, 186–193. [Google Scholar] [CrossRef]
  97. Morris, B.J.; Willcox, D.C.; Donlon, T.A.; Willcox, B.J. 2012 FOXO3: A major gene for human longevity-a mini-review. Gerontology 2015, 61, 515–525. [Google Scholar] [CrossRef] [Green Version]
  98. Chhabra, R.; Saha, A.; Chamani, A.; Schneider, N.; Nanjundan, M.; Shah, R. Iron Pathways and Iron Chelation Approaches in Viral, Microbial, and Fungal Infections. Pharmaceuticals 2020, 13, 275. [Google Scholar] [CrossRef]
  99. Brem, H.; Stojadinovic, O.; Diegelmann, R.F.; Entero, H.; Lee, B.; Pastar, I.; Golinko, M.; Rosenberg, H.; Tomic-Canic, M. Cholinergic Anti-Inflammatory Pathway Activity and High High Mobility Group Box-1 (HMGB1) Serum Levels in Patients with Rheumatoid Arthritis. Mol. Med. 2007, 13, 30–39. [Google Scholar] [CrossRef]
  100. Wang, Q.; Liu, Y.; An, D.; Diao, H.; Xu, W.; He, X.; Sun, R.; Wei, L.; Li, L. Regulation of Hepatitis C Virus Translation Initiation by Iron: Role of EIF3 and La Protein. Virus Res. 2012, 167, 302–309. [Google Scholar] [CrossRef]
  101. Vela, D. Low Hepcidin in Liver Fibrosis and Cirrhosis; A Tale of Progressive Disorder and a Case for a New Biochemical Marker. Mol. Med. 2018, 24, 1–18. [Google Scholar] [CrossRef] [PubMed]
  102. Mansouri, A.; Gaou, I.; Fromenty, B.; Berson, A.; Letteron, P.; Degott, C.; Erlinger, S.; Pessayre, D. “Premature MtDNA Deletions in Wilson’s Livers” Premature Oxidative Aging of Hepatic Mitochondrial DNA in Wilson’s Disease. Gastroenterology 1997, 113, 599–605. [Google Scholar] [CrossRef] [PubMed]
  103. Yu, L.; Liou, I.W.; Biggins, S.W.; Yeh, M.; Jalikis, F.; Chan, L.N.; Burkhead, J. Copper Deficiency in Liver Diseases: A Case Series and Pathophysiological Considerations. Hepatol. Commun. 2019, 3, 1159–1165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Pauff, S.M.; Miller, S.C. High Fructose Feeding Induces Copper Deficiency in SpragueDawley Rats: A Novel Mechanism for Obesity Related Fatty Liver. Bone 2012, 78, 711–716. [Google Scholar] [CrossRef]
  105. Jorquera, F.; Monte, M.J.; Guerra, J.; Sanchez-Campos, S.; Merayo, J.A.; Olcóz, J.L.; González-Gallego, J.; Marin, J.J.G. Usefulness of Combined Measurement of Serum Bile Acids and Ferritin as Additional Prognostic Markers to Predict Failure to Reach Sustained Response to Antiviral Treatment in Chronic Hepatitis C. J. Gastroenterol. Hepatol. 2005, 20, 547–554. [Google Scholar] [CrossRef]
  106. Escobedo-Monge, M.F.; Barrado, E.; Parodi-Román, J.; Escobedo-Monge, M.A.; Torres-Hinojal, M.C.; Marugán-Miguelsanz, J.M. Copper and Copper/Zn Ratio in a Series of Children with Chronic Diseases: A Cross-Sectional Study. Nutrients 2021, 13, 3578. [Google Scholar] [CrossRef]
  107. Sunada, K.; Minoshima, M.; Hashimoto, K. Highly Efficient Antiviral and Antibacterial Activities of Solid-State Cuprous Compounds. J. Hazard. Mater. 2012, 235, 265–270. [Google Scholar] [CrossRef]
  108. Deng, S.; Tjoa, V.; Fan, H.M.; Tan, H.R.; Sayle, D.C.; Olivo, M.; Mhaisalkar, S.; Wei, J.; Sow, C.H. Reduced Graphene Oxide Conjugated Cu2O Nanowire Mesocrystals for High-Performance NO2 Gas Sensor. J. Am. Chem. Soc. 2012, 134, 4905–4917. [Google Scholar] [CrossRef]
  109. Singh, J.; Srivastava, M.; Roychoudhury, A.; Lee, D.W.; Lee, S.H.; Malhotra, B.D. Bienzyme-Functionalized Monodispersed Biocompatible Cuprous Oxide/Chitosan Nanocomposite Platform for Biomedical Application. J. Phys. Chem. B 2013, 117, 141–152. [Google Scholar] [CrossRef]
  110. Joshi, S.; Joshi, M.; Degani, M.S. Tackling SARS-CoV-2: Proposed Targets and Repurposed Drugs. Future Med. Chem. 2020, 12, 1579–1601. [Google Scholar] [CrossRef]
  111. Basu, S. Non-Communicable Disease Management in Vulnerable Patients during COVID-19. Indian J. Med. Ethics 2020, 2, 103–105. [Google Scholar] [CrossRef] [PubMed]
  112. Guillin, O.M.; Vindry, C.; Ohlmann, T.; Chavatte, L. Selenium, Selenoproteins and Viral Infection. Nutrients 2019, 11, 2101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  113. Kieliszek, M.; Lipinski, B. Selenium supplementation in the prevention of coronavirus infections (COVID-19). Med. Hypotheses 2020, 143, 109878. [Google Scholar] [CrossRef] [PubMed]
  114. Martínez-González, J.; Varona, S.; Cañes, L.; Galán, M.; Briones, A.M.; Cachofeiro, V.; Rodríguez, C. Emerging Roles of Lysyl Oxidases in the Cardiovascular System: New Concepts and Therapeutic Challenges. Biomolecules 2019, 9, 610. [Google Scholar] [CrossRef] [Green Version]
  115. Cherukuri, S.; Potla, R.; Sarkar, J.; Nurko, S.; Harris, Z.L.; Fox, P.L. Unexpected Role of Ceruloplasmin in Intestinal Iron Absorption. Cell Metab. 2005, 2, 309–319. [Google Scholar] [CrossRef] [Green Version]
  116. Cassat, J.E.; Skaar, E.P. Iron in Infection and Immunity. Cell Host Microbe 2013, 13, 509–519. [Google Scholar] [CrossRef] [Green Version]
  117. Tarifeño-Saldivia, E.; Aguilar, A.; Contreras, D.; Mercado, L.; Morales-Lange, B.; Márquez, K.; Henríquez, A.; Riquelme-Vidal, C.; Boltana, S. Iron Overload Is Associated with Oxidative Stress and Nutritional Immunity during Viral Infection in Fish. Front. Immunol. 2018, 9, 1296. [Google Scholar] [CrossRef] [Green Version]
  118. Bastin, A.; Shiri, H.; Zanganeh, S.; Fooladi, S.; Momeni Moghaddam, M.A.; Mehrabani, M.; Nematollahi, M.H. Iron Chelator or Iron Supplement Consumption in COVID-19? The Role of Iron with Severity Infection. Biol. Trace Elem. Res. 2021, 25, 1–11. [Google Scholar] [CrossRef]
  119. Woodby, B.; Arnold, M.M.; Valacchi, G. SARS-CoV-2 Infection, COVID-19 Pathogenesis, and Exposure to Air Pollution: What Is the Connection? Ann. N. Y. Acad. Sci. 2021, 1486, 15–38. [Google Scholar] [CrossRef]
  120. Shahid, Z.; Kalayanamitra, R.; McClafferty, B.; Kepko, D.; Ramgobin, D.; Patel, R.; Aggarwal, C.S.; Vunnam, R.; Sahu, N.; Bhatt, D.; et al. COVID-19 and Older Adults: What We Know. J. Am. Geriatr. Soc. 2020, 68, 926–929. [Google Scholar] [CrossRef] [Green Version]
  121. Choi, S.H.; Kim, H.W.; Kang, J.M.; Kim, D.H.; Cho, E.Y. Epidemiology and Clinical Features of Coronavirus Disease 2019 in Children. Korean J. Pediatr. 2020, 63, 125–132. [Google Scholar] [CrossRef] [Green Version]
  122. Kernan, K.F.; Carcillo, J.A. Hyperferritinemia and Inflammation. Int. Immunol. 2017, 29, 401–409. [Google Scholar] [CrossRef] [PubMed]
  123. Edeas, M.; Saleh, J.; Peyssonnaux, C. Iron: Innocent Bystander or Vicious Culprit in COVID-19 Pathogenesis? Int. J. Infect. Dis. 2020, 97, 303–305. [Google Scholar] [CrossRef] [PubMed]
  124. Leermakers, P.A.; Remels, A.H.V.; Zonneveld, M.I.; Rouschop, K.M.A.; Schols, A.M.W.J.; Gosker, H.R. Iron Deficiency-Induced Loss of Skeletal Muscle Mitochondrial Proteins and Respiratory Capacity; the Role of Mitophagy and Secretion of Mitochondria-Containing Vesicles. FASEB J. 2020, 34, 6703–6717. [Google Scholar] [CrossRef] [Green Version]
  125. Ersöz, A.; Yılmaz, T.E. The Association between Micronutrient and Hemogram Values and Prognostic Factors in COVID-19 Patients: A Single-Center Experience from Turkey. Int. J. Clin. Pract. 2021, 75, 1–9. [Google Scholar] [CrossRef]
  126. Ganz, T.; Nemeth, E. Iron Sequestration and Anemia of Inflammation. Semin. Hematol. 2009, 46, 387–393. [Google Scholar] [CrossRef] [Green Version]
  127. Augustine, L.F.; Mullapudi, V.; Subramanian, S.; Kulkarni, B. Infection-Iron Interaction during COVID-19 Pandemic: Time to Re-Design Iron Supplementation Programs. Med. Hypotheses 2020, 143, 110173. [Google Scholar] [CrossRef]
  128. Habib, H.M.; Ibrahim, S.; Zaim, A.; Ibrahim, W.H. The Role of Iron in the Pathogenesis of COVID-19 and Possible Treatment with Lactoferrin and Other Iron Chelators. Biomed. Pharmacother. 2020, 136, 111228. [Google Scholar] [CrossRef]
  129. Kell, D.B.; Heyden, E.L.; Pretorius, E. The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria. Front. Immunol. 2020, 11, 1221. [Google Scholar] [CrossRef]
  130. Tinkov, A.A.; Ajsuvakova, O.P.; Shehtman, A.M.; Boev, V.M.; Nikonorov, A.A. Influence of Iron and Copper Consumption on Weight Gain and Oxidative Stress in Adipose Tissue of Wistar Rats. Interdiscip. Toxicol. 2012, 5, 127–132. [Google Scholar] [CrossRef]
  131. Dubey, P.; Thakur, V.; Chattopadhyay, M. Role of Minerals and Trace Elements in Diabetes and Insulin Resistance. Nutrients 2020, 12, 1864. [Google Scholar] [CrossRef] [PubMed]
  132. Cruz, K.J.C.; De Oliveira, A.R.S.; Morais, J.B.S.; Severo, J.S.; Mendes, P.M.V.; Melo, S.R.d.; De Sousa, G.S. Zinc and Insulin Resistance: Biochemical and Molecular Aspects. Biol. Trace Elem. Res. 2018, 186, 407–412. [Google Scholar] [CrossRef]
  133. Tamaki, M.; Fujitani, Y.; Hara, A.; Uchida, T.; Tamura, Y.; Takeno, K.; Kawaguchi, M.; Watanabe, T.; Ogihara, T.; Fukunaka, A.; et al. The Diabetes-Susceptible Gene SLC30A8/ZnT8 Regulates Hepatic Insulin Clearance. J. Clin. Investig. 2013, 123, 4513–4524. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  134. Ranasinghe, P.; Wathurapatha, W.S.; Galappatthy, P.; Katulanda, P.; Jayawardena, R.; Constantine, G.R. Zinc Supplementation in Prediabetes: A Randomized Double-Blind Placebo-Controlled Clinical Trial. J. Diabetes 2018, 10, 386–397. [Google Scholar] [CrossRef] [PubMed]
  135. Sun, Q.; Van Dam, R.M.; Willett, W.C.; Hu, F.B. Prospective Study of Zinc Intake and Risk of Type 2 Diabetes in Women. Diabetes Care 2009, 32, 629–634. [Google Scholar] [CrossRef] [Green Version]
  136. Schomburg, L. Selenium Deficiency Due to Diet, Pregnancy, Severe Illness, or COVID-19—A Preventable Trigger for Autoimmune Disease. Int. J. Mol. Sci. 2021, 22, 8532. [Google Scholar] [CrossRef]
  137. Roden, M.; Shulman, G.I. The Integrative Biology of Type 2 Diabetes. Nature 2019, 576, 51–60. [Google Scholar] [CrossRef] [Green Version]
  138. Steinbrenner, H.; Duntas, L.H.; Rayman, M.P. The Role of Selenium in Type-2 Diabetes Mellitus and Its Metabolic Comorbidities. Redox Biol. 2022, 50, 102236. [Google Scholar] [CrossRef]
  139. Kim, J.; Chung, H.S.; Choi, M.K.; Roh, Y.K.; Yoo, H.J.; Park, J.H.; Kim, D.S.; Yu, J.M.; Moon, S. Association between Serum Selenium Level and the Presence of Diabetes Mellitus: A Meta-Analysis of Observational Studies. Diabetes Metab. J. 2019, 43, 447–460. [Google Scholar] [CrossRef]
  140. Stranges, S.; Galletti, F.; Farinaro, E.; D’Elia, L.; Russo, O.; Iacone, R.; Capasso, C.; Carginale, V.; De Luca, V.; Della Valle, E.; et al. Associations of Selenium Status with Cardiometabolic Risk Factors: An 8-Year Follow-up Analysis of the Olivetti Heart Study. Atherosclerosis 2011, 217, 274–278. [Google Scholar] [CrossRef]
  141. Alghobashy, A.A.; Alkholy, U.M.; Talat, M.A.; Abdalmonem, N.; Zaki, A.; Ahmed, I.A.; Mohamed, R.H. Trace Elements and Oxidative Stress in Children with Type 1 Diabetes Mellitus. Diabetes Metab. Syndr. Obes. Targets Ther. 2018, 11, 85–92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  142. Vinceti, M.; Filippini, T.; Wise, L.A.; Rothman, K.J. A Systematic Review and Dose-Response Meta-Analysis of Exposure to Environmental Selenium and the Risk of Type 2 Diabetes in Nonexperimental Studies. Environ. Res. 2021, 197, 111210. [Google Scholar] [CrossRef] [PubMed]
  143. Liao, X.L.; Wang, Z.H.; Liang, X.N.; Liang, J.; Wei, X.B.; Wang, S.H.; Guo, W.X. The Association of Circulating Selenium Concentrations with Diabetes Mellitus. Diabetes Metab. Syndr. Obes. Targets Ther. 2020, 13, 4755–4761. [Google Scholar] [CrossRef] [PubMed]
  144. Cheng, Z.; Li, Y.; Young, J.L.; Cheng, N.; Yang, C.; Papandonatos, G.D.; Kelsey, K.T.; Wise, J.P.; Shi, K.; Zheng, T.; et al. Long-Term Association of Serum Selenium Levels and the Diabetes Risk: Findings from a Case-Control Study Nested in the Prospective Jinchang Cohort. Sci. Total Environ. 2022, 818, 151848. [Google Scholar] [CrossRef] [PubMed]
  145. Panel, E.; Nda, A. Scientific Opinion on Dietary Reference Values for Magnesium. EFSA J. 2015, 13, 1–63. [Google Scholar] [CrossRef] [Green Version]
  146. Lobionda, S.; Sittipo, P.; Kwon, H.Y.; Lee, Y.K. The Role of Gut Microbiota in Intestinal Inflammation with Respect to Diet and Extrinsic Stressors. Microorganisms 2019, 7, 271. [Google Scholar] [CrossRef] [Green Version]
  147. Gill, J.M.R. Type 2 Diabetes. Nurs. Made Incred. Easy 2012, 10, 30–31. [Google Scholar] [CrossRef]
  148. Fang, X.; Han, H.; Li, M.; Liang, C.; Fan, Z.; Aaseth, J.; He, J.; Montgomery, S.; Cao, Y. Dose-Response Relationship between Dietary Magnesium Intake and Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Regression Analysis of Prospective Cohort Studies. Nutrients 2016, 8, 739. [Google Scholar] [CrossRef]
  149. Kostov, K. Effects of Magnesium Deficiency on Mechanisms of Insulin Resistance in Type 2 Diabetes: Focusing on the Processes of Insulin Secretion and Signaling. Int. J. Mol. Sci. 2019, 20, 1351. [Google Scholar] [CrossRef] [Green Version]
  150. Apell, H.J.; Hitzler, T.; Schreiber, G. Modulation of the Na,K-ATPase by Magnesium Ions. Biochemistry 2017, 56, 1005–1016. [Google Scholar] [CrossRef]
  151. Zhao, B.; Zeng, L.; Zhao, J.; Wu, Q.; Dong, Y.; Zou, F.; Gan, L.; Wei, Y.; Zhang, W. Association of Magnesium Intake with Type 2 Diabetes and Total Stroke: An Updated Systematic Review and Meta-Analysis. BMJ Open 2020, 10, e032240. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  152. Jayawardena, R.; Ranasinghe, P.; Galappatthy, P.; Malkanthi, R.L.; Constantine, G.R.; Katulanda, P. Effects of Zinc Supplementation on Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetol. Metab. Syndr. 2012, 4, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  153. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT05320510?term=selenium&cond=diabetes+type+2&draw=2&rank=1 (accessed on 11 May 2022).
  154. Saeed, H.; Haj, S.; Qasim, B. Estimation of Magnesium Level in Type 2 Diabetes Mellitus and Its Correlation with HbA1c Level. Endocrinol. Diabetes Metab. 2019, 19, 41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  155. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03002545?term=magnesium&cond=type+2+diabetes&draw=2&rank=3 (accessed on 11 May 2022).
  156. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT05033054?term=magnesium&cond=type+2+diabetes&draw=2&rank=6 (accessed on 11 May 2022).
  157. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=selenium&cntry=&state=&city=&dist= (accessed on 11 May 2022).
  158. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04877509?term=selenium&cond=COVID-19&draw=2&rank=2 (accessed on 11 May 2022).
  159. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04941703?term=magnesium&cond=covid19&draw=2&rank=1 (accessed on 11 May 2022).
  160. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04716985?term=magnesium&cond=covid19&draw=2&rank=3 (accessed on 11 May 2022).
  161. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04641195?term=zinc&cond=COVID-19&draw=2&rank=1 (accessed on 11 May 2022).
  162. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04370782?term=zinc&cond=COVID-19&draw=2&rank=2 (accessed on 11 May 2022).
  163. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04558424?term=zinc&cond=COVID-19&draw=2&rank=3 (accessed on 11 May 2022).
  164. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04542993?term=zinc&cond=COVID-19&draw=2&rank=6 (accessed on 11 May 2022).
  165. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04072822?term=zinc&cond=hepatitis&draw=2&rank=1 (accessed on 11 May 2022).
  166. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT01809132?term=zinc&cond=hepatitis&draw=2&rank=2 (accessed on 11 May 2022).
  167. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT01355107?term=selenium&cond=hepatitis&draw=2&rank=1 (accessed on 11 May 2022).
  168. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03349008?term=magnesium&cond=hepatitis&draw=2&rank=1 (accessed on 11 May 2022).
  169. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03166280?term=NCT03166280&draw=2&rank=1 (accessed on 11 May 2022).
  170. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT02744560?term=iron&cond=hepatitis&draw=2&rank=4 (accessed on 11 May 2022).
Nutrients 14 02632 g001 550
Figure 1. Roles of serum zinc and methallothionein in acute versus chronic hepatitis C virus (HCV).
Figure 1. Roles of serum zinc and methallothionein in acute versus chronic hepatitis C virus (HCV).
Nutrients 14 02632 g001
Nutrients 14 02632 g002 550
Figure 2. The role of dietary selenium (Se) in viral infections.
Figure 2. The role of dietary selenium (Se) in viral infections.
Nutrients 14 02632 g002
Nutrients 14 02632 g003 550
Figure 3. The mechanism of action and expression of hepcidin.
Figure 3. The mechanism of action and expression of hepcidin.
Nutrients 14 02632 g003
Nutrients 14 02632 g004 550
Figure 4. The relationship between magnesium (Mg) and insulin signalling and resistance.
Figure 4. The relationship between magnesium (Mg) and insulin signalling and resistance.
Nutrients 14 02632 g004
Table
Table 1. Pathogenic pathways and roles of a number of micronutrients in the prevention and/or treatment of chronic hepatitis, COVID-19 and type-2 diabetes mellitus.
Table 1. Pathogenic pathways and roles of a number of micronutrients in the prevention and/or treatment of chronic hepatitis, COVID-19 and type-2 diabetes mellitus.
Chronic Hepatitis
Zinc (Zn)
  • The two human zinc finger antiviral protein (hZAP) isoforms (i.e., h-ZAP S; h-ZAP L) inhibited the replication of HBV in human hepatocyte-derived cells [31].
  • Knock-down of the expression of ZAP increased the HBV RNA levels and caused a partial attenuation of the antiviral effect stimulated by IPS-1 in the cell cultures used [32].
  • Zinc (Zn) serum levels were shown to rise significantly upon viral eradication using interferon (IFN)-based regimens or direct-acting anti-viral (DAA) therapy [33].
  • Zinc (Zn) treatment was shown to significantly inhibit the replication of the virus in the human hepatoma cell culture of genotype-1 and genotype-3 HEV by inhibiting the RNA-dependent RNA polymerase (RdRp) viral activity in vitro [7].
  • A decline in the serum levels of zinc following an IFN-α treatment resulted in an increase in the baseline zinc (Zn) levels, causing a stimulation of the metallothionein (MT) expression and the anti-viral activity [34].
Selenium (Se)
  • CHC infection reduced the serum levels of selenium (Se) and the activity of glutathion peroxidase (GPx) [35,36].
Iron (Fe)
  • An enhancement in the progression of chronic HBV infection was related to the high iron (Fe) serum levels [37].
  • The levels of serum iron (Fe) and serum ferritin were increased in patients with chronic hepatitis B (CHB) [38].
  • Some inflammatory factors, such as liver injury, micro ribonucleic acid -122, viral activity, ROS, IL-6 could result in an iron (Fe) overload in patients with CHB [39].
  • The replication of HCV was shown to enhance in iron (Fe) overloaded macrophages as compared to the iron (Fe) physiological level due to the high oxidative stress in the macrophages and the impairment in the immune function [40].
Copper (Cu)
  • Acute HCV infection increased serum copper (Cu) as it binds to MTs (Cu–MTs), hence leading to hepatic copper overload [6].
  • HCV-mediated inhibition of the secretion of bile acid may cause a retention of the biliary copper(Cu) [41].
  • Over-supplementation of zinc (Zn) could result in a copper (Cu) deficiency due to the inhibition of the copper absorption in the gut [4].
  • Cuprous oxide nanoparticles (CO-NPs) inhibit the HCV cell cultures infectivity at a non-cytotoxic concentration [5].
COVID-19
Zinc (Zn)
  • Zinc (Zn) inhibits replicase polyproteins proteolytic processing and inhibits the activity of RNA-dependent RNA polymerase (RdRp) [42].
  • Giving a high-dose intravenous zinc (HDIVZn) provides a protection to various body organs, such as the heart, liver and kidneys against the hypoxic damage [43].
  • The combination of zinc (Zn) with ionophore have a synergistic action, which could be powerful for elderly patients with COVID-19 [44].
Selenium (Se)
  • The provinces that have high concentrations of selenium (Se) in the soils showed lower fatality from COVID-19 as compared to other areas with selenium (Se) deficient soils [45].
  • Selenium (Se) deficiency in patients with COVID-19 was shown to be related to mutations, replication, as well as virulence of RNA viruses [46].
  • Low selenium (Se) levels were noticed widely in patients with a higher risk of developing a severe COVID-19 infection and, in particular in senior individuals [47].
  • Severe selenium (Se) deficiency is associated with poor survival rates in COVID-19 [48].
Copper (Cu)
  • Serum levels of copper (Cu) were shown to increase in pregnant women with COVID-19 particularly in the first and the third trimesters [49].
  • Copper (Cu) serum levels are generally increased in patients with severe COVID-19 infection [20].
  • A decrease in copper (Cu) concentrations was seen at ICU admission [50].
  • Copper (Cu) supplementation has an important role in regulating IL-2 and plays an important role in managing the immune dysregulation in critically ill COVID-19 patients [51].
Type-2 Diabetes Mellitus (T2DM)
Zinc (Zn)
  • Zinc (Zn) has a distinctive role in the regulation of glycemic control due to its antioxidant characteristics.
  • Zinc (Zn) stimulates glycolysis, decreases gluconeogenesis and inhibits the activity of alpha-glucosidase in the intestine [30].
  • Higher serum levels of zinc (Zn) are associated with an increased T2DM risk [52].
  • Higher serum levels of zinc (Zn) are associated with a decreased insulin resistance [53].
  • Pancreatic β cells have a high concentration of zinc (Zn) when compared to other cells types [54].
  • A negative correlation between plasma concentrations of zinc (Zn) and the onset of diabetes was reported [55].
  • Over-supplementation of zinc (Zn) may increase the levels of HbA1c and blood pressure [55].
Selenium (Se)
  • Selenium (as selenate) has anti-diabetic, as well as insulin-mimetic properties, at high doses [56].
  • Higher plasma concentration of selenium (Se) was associated with a higher T2DM occurrence [57].
Magnesium (Mg)
  • Magnesium (Mg) deficiency has been frequently reported in obese subjects and is observed in diabetic patients or in those with metabolic syndromes [58].
  • Magnesium (Mg) deficiency increases the risk for T2DM [59].
  • T2DM is characterized with an altered homeostasis of magnesium (Mg) [60].
  • A high prevalence of hypomagnesemia in type-2 diabetic subjects was detected [61].
Table
Table 2. Database of clinical trials on zinc (Zn), selenium (Se), copper (Cu), magnesium (Mg) and iron (Fe) interventions against hepatitis, covid19 and type-2 diabetes mellitus.
Table 2. Database of clinical trials on zinc (Zn), selenium (Se), copper (Cu), magnesium (Mg) and iron (Fe) interventions against hepatitis, covid19 and type-2 diabetes mellitus.
ClinicalTials.gov IdentifierStudy TitleConditionIntervention & FindingsStatusReference
NCT05000762Zinc Supplementation Improves Cardiovascular Morbidity in Patients with Diabetes MellitusDiabetes Mellitus, Type 2
Cardiovascular Diseases		Dietary Supplement: Zinc (Zn)
Zinc gluconate 30 mg/day orally		Recruiting[152]
NCT05320510Effect of Selenium (Se) Supplementation on Glycemic Control in Patients with Type 2 Diabetes or PrediabetesType 2 Diabetes
Pre Diabetes		Dietary Supplement: Se-yeast
The participants will be asked to take Se-yeast tablet.
Dietary Supplement: Placebo
The participants will be asked to take placebo-yeast tablet.		Not yet recruiting[153]
NCT04636411Effect of Oral Magnesium Supplementation on Patients with Type 2 DiabetesType2 DiabetesDietary Supplement: Oral Magnesium (Mg) Supplementation
Other: Standard Care for diabetic patients		Recruiting[154]
NCT03002545Magnesium Supplementation in Type II DiabetesEffect of magnesium (Mg) in diabetesDietary Supplement: Magnesium (Mg) citrate Dietary Supplement: Placebo
Findings: oral Mg citrate supplementation reduced HbA1c levels and reduced BP in normomagnesemic persons with MetS		Completed[155]
NCT05033054Effect of Dietary Magnesium Supplementation vs. Dapagliflozin in Patients with Diabetic Kidney Disease (DKD)Kidney Disease,
Chronic Diabetes		Dietary Supplement: EffCaMg Citrate 480 mg Drug: Dapagliflozin 10 mg
Dietary Supplement: Placebo EffCaMg Citrate Drug: Placebo Dapagliflozin		Not yet recruiting[156]
NCT04869579Selenium (Se) as a Potential Treatment for Moderately-ill, Severely-ill and Critically-ill COVID-19 Patients.Covid19Drug: Selenium (as Selenious Acid)Other: PlaceboNot yet recruiting[157]
NCT04877509Micronutrient Status Involved in Immunity in Elderly Patients with COVID-19Covid19Biological: Selenium (Se), Zinc (Zn) and Copper (Cu), Vitamin A, D, E plasma concentrations during patient hospitalizationCompleted[158]
NCT04941703CHANGE COVID-19 SeverityCOVID-19 InfectionDrug: Magnesium Citrate plus probioticRecruiting[159]
NCT04716985Evaluation of the Daily Intake of 0.5 L of Water Saturated with Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory CareSARS-CoV-2
Covid19
AMBULATORY CARE		Dietary Supplement: molecular hydrogen
Dietary Supplement: placebo magnesium (Mg)		Active not recruiting[160]
NCT04641195Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in IndiaCovid19Dietary Supplement: Vitamin D3 (cholecalciferol)
Dietary Supplement: Zinc (zinc gluconate)
Dietary Supplement: Zinc (zinc gluconate) & Vitamin D (cholecalciferol)
Other: Placebo		recruiting[161]
NCT04370782Hydroxychloroquine and Zinc with Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient SettingCovid19Drug: Hydroxychloroquine
Drug: Azithromycin
Drug: Zinc Sulfate
Drug: Doxycycline		Completed[162]
NCT04558424RCT, Double Blind, Placebo to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMUCovid19Dietary Supplement: zinc gluconate and ascorbic acidNot yet recruiting[163]
NCT04542993Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity Be Reduced by Resveratrol-assisted Zinc Therapy (Reszinate)Covid19
SARS-CoV Infection		Dietary Supplement: Zinc Picolinate
Dietary Supplement: Resveratrol
Dietary Supplement: Zinc Picolinate Placebo
Dietary Supplement: Resveratrol Placebo		Active, not recruiting[164]
NCT04072822Trial of Anakinra (Plus Zinc) or Prednisone in Patients with Severe Alcoholic HepatitisAlcoholic HepatitisDrug: Anakinra and Zinc (Zn)
Drug: Prednisone
Drug: Placebos		Active, not recruiting[165]
NCT01809132Efficacy Study of Anakinra, Pentoxifylline and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic HepatitisAcute Alcoholic HepatitisDrug: Anakinra
Drug: Pentoxifylline
Drug: Zinc Sulfate
Drug: Methylprednisolone		Completed, has results[166]
NCT01355107Comparison of Selenium (Se) Levels in HCV- Infected Patients at Different Stages of DiseaseHepatitis C
Liver Cirrhosis
Carcinoma, Hepatocellular		N/ACompleted[167]
NCT03349008Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined with Entecavir in Chronic Hepatitis BChronic Hepatitis B
Liver Inflammation		Drug: Entecavir
Drug: Magnesium Isoglycyrrhizinate
Drug: Diammonium Glycyrrhizinate
Drug: Magnesium Isoglycyrrhizinate Placebo
Drug: Diammonium Glycyrrhizinate Placebo		N/A[168]
NCT03166280Hepatitis c and Vitamin D and Iron (Fe) Status
Hepatitis CDrug: Sofosbuvir 400 mg
Drug: Daclatasvir 60 mg/day		N/A[169]
NCT02744560Effect of Spirulina on Liver Iron (Fe) Concentration in Beta Thalassemic Children with Hepatitis CBeta Thalassemia MajorDietary Supplement: spirulinaCompleted[170]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Sumaily, K.M. The Roles and Pathogenesis Mechanisms of a Number of Micronutrients in the Prevention and/or Treatment of Chronic Hepatitis, COVID-19 and Type-2 Diabetes Mellitus. Nutrients 2022, 14, 2632. https://doi.org/10.3390/nu14132632

AMA Style

Sumaily KM. The Roles and Pathogenesis Mechanisms of a Number of Micronutrients in the Prevention and/or Treatment of Chronic Hepatitis, COVID-19 and Type-2 Diabetes Mellitus. Nutrients. 2022; 14(13):2632. https://doi.org/10.3390/nu14132632

Chicago/Turabian Style

Sumaily, Khalid M. 2022. "The Roles and Pathogenesis Mechanisms of a Number of Micronutrients in the Prevention and/or Treatment of Chronic Hepatitis, COVID-19 and Type-2 Diabetes Mellitus" Nutrients 14, no. 13: 2632. https://doi.org/10.3390/nu14132632

APA Style

Sumaily, K. M. (2022). The Roles and Pathogenesis Mechanisms of a Number of Micronutrients in the Prevention and/or Treatment of Chronic Hepatitis, COVID-19 and Type-2 Diabetes Mellitus. Nutrients, 14(13), 2632. https://doi.org/10.3390/nu14132632

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop